{"protocolSection":{"identificationModule":{"nctId":"NCT00518336","orgStudyIdInfo":{"id":"109616 (Y7)"},"secondaryIdInfos":[{"id":"109624","type":"OTHER","domain":"GSK"},{"id":"109625","type":"OTHER","domain":"GSK"}],"organization":{"fullName":"GlaxoSmithKline","class":"INDUSTRY"},"briefTitle":"Follow-up Study to Evaluate the Long-term Efficacy of the HPV Vaccine (580299) in Healthy Young Adult Women in Brazil","officialTitle":"Follow-up Study to Evaluate the Long-term Efficacy of a HPV Vaccine (580299) in Healthy Young Adult Women in Brazil"},"statusModule":{"statusVerifiedDate":"2016-10","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2007-11"},"primaryCompletionDateStruct":{"date":"2008-07","type":"ACTUAL"},"completionDateStruct":{"date":"2010-09","type":"ACTUAL"},"studyFirstSubmitDate":"2007-08-17","studyFirstSubmitQcDate":"2007-08-17","studyFirstPostDateStruct":{"date":"2007-08-20","type":"ESTIMATED"},"resultsFirstSubmitDate":"2010-07-12","resultsFirstSubmitQcDate":"2011-09-15","resultsFirstPostDateStruct":{"date":"2011-10-25","type":"ESTIMATED"},"lastUpdateSubmitDate":"2016-10-27","lastUpdatePostDateStruct":{"date":"2016-12-09","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"GlaxoSmithKline","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. This Phase IIb study is designed to evaluate the the long-term efficacy, safety and immunogenicity of the 580299 HPV vaccine (CervarixTM) in a Brazilian cohort of women vaccinated in the phase IIb, blinded, primary study 580299/001 (NCT00689741) and having participated in follow-up study 580299/007 (NCT00120848). Only subjects who participated in the primary \\& follow-up study will be enrolled in this long-term follow-up study. Subjects were aged 15-25 years at the time of entry into the primary study.\n\nThe Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.","detailedDescription":"In this extension study, women who were vaccinated in the primary study, and participated in the follow-up study, will be followed with visits every 6 months."},"conditionsModule":{"conditions":["Infections, Papillomavirus"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":433,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Cervarix Group","type":"EXPERIMENTAL","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study.","interventionNames":["Procedure: Blood sampling","Procedure: Collection of cervical specimen","Biological: Cervarix"]},{"label":"Placebo Group","type":"PLACEBO_COMPARATOR","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study.","interventionNames":["Procedure: Blood sampling","Procedure: Collection of cervical specimen"]}],"interventions":[{"type":"PROCEDURE","name":"Blood sampling","description":"Blood sampling at Visit 3, 5 and 7.","armGroupLabels":["Cervarix Group","Placebo Group"]},{"type":"PROCEDURE","name":"Collection of cervical specimen","description":"Collection of cervical specimen at Visit2, 3, 4, 5, 6 and 7.","armGroupLabels":["Cervarix Group","Placebo Group"]},{"type":"BIOLOGICAL","name":"Cervarix","description":"Three doses administered intramuscularly at 0, 1 and 6 months.","armGroupLabels":["Cervarix Group"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Subjects Presenting Cervical Infections With Human Papillomavirus (HPV) -16 and/or HPV-18","description":"Cervical HPV infection was defined as the first detection of an HPV type in a subject previously negative for that HPV type.","timeFrame":"Up to year 8"},{"measure":"Number of Subjects Presenting Cervical Infections With Human Papillomavirus (HPV) -16 and/or HPV-18","description":"Cervical HPV infection was defined as the first detection of an HPV type in a subject previously negative for that HPV type","timeFrame":"Up to year 9"},{"measure":"Number of Subjects Presenting Cervical Infections With Human Papillomavirus (HPV) -16 and /or HPV-18","description":"Cervical HPV infection was defined as the first detection of an HPV type in a subject previously negative for that HPV type.","timeFrame":"Up to year 7"}],"secondaryOutcomes":[{"measure":"Number of Subjects Presenting Cervical Infections With Any Oncogenic HPV Type","description":"Oncogenic HPV types included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had a normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at month 6 in the primary study.","timeFrame":"Up to year 8"},{"measure":"Number of Subjects Presenting Cervical Infections With Individual Oncogenic Non-vaccine HPV Type","description":"Oncogenic types included HPV-31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies and were DNA negative for the corresponding HPV type at month 6 in the primary study.","timeFrame":"Up to year 8"},{"measure":"Number of Subjects With Persistent Infection (6-month Definition) With HPV-16 and/or HPV-18","description":"Persistent cervical HPV infection (6-month definition) was defined as detection of the same HPV type in cervical specimens at 2 consecutive evaluations over a minimum of 5 months.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had a normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at month 6 in the primary study.","timeFrame":"Up to year 8"},{"measure":"Number of Subjects With Persistent Infection (6-month Definition) With Any Oncogenic HPV Types","description":"Oncogenic HPV types included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nPersistent cervical HPV infection (6-month definition) was defined as detection of the same HPV type in cervical specimens at 2 consecutive evaluations over a minimum of 5 months.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had a normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at month 6 in the primary study.","timeFrame":"Up to year 8"},{"measure":"Number of Subjects With Persistent Infection (6-month Definition) With Individual Oncogenic Non-vaccine HPV Types","description":"Oncogenic HPV types included HPV-31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nPersistent cervical HPV infection (6-month definition) was defined as detection of the same HPV type in cervical specimens at 2 consecutive evaluations over a minimum of 5 months.\n\nSubjects with an event did not report the same event during the earlier studies. Subjects with an event were DNA negative for the corresponding HPV type at Month 6 in the primary study.","timeFrame":"Up to year 8"},{"measure":"Number of Subjects With Persistent Infection (12-month Definition) With HPV-16 and/or HPV-18","description":"Persistent cervical HPV infection (12-month definition) was defined as detection of the same HPV type in cervical specimens at all consecutive evaluations over a minimum of 10 months.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had a normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at month 6 in the primary study.","timeFrame":"Up to year 8"},{"measure":"Number of Subjects With Persistent Infection (12-month Definition) With Any Oncogenic HPV Types","description":"Oncogenic HPV types included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nPersistent cervical HPV infection (12-month definition) was defined as detection of the same HPV type in cervical specimens at all consecutive evaluations over a minimum of 10 months.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had a normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at month 6 in the primary study.","timeFrame":"Up to year 8"},{"measure":"Number of Subjects With Persistent Infection (12-month Definition) With Individual Oncogenic Non-vaccine HPV Types","description":"Individual oncogenic non-vaccine HPV types include HPV-31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nPersistent cervical HPV infection (12-month definition) was defined as detection of the same HPV type in cervical specimens at all consecutive evaluations over a minimum of 10 months.\n\nSubjects with an event did not report the same event in the earlier studies and were DNA negative for the corresponding HPV type at month 6 in the primary study.","timeFrame":"Up to year 8"},{"measure":"Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With HPV-16 or HPV-18 Detected Within the Lesional Component of the Cervical Tissue Specimen","description":"CIN1+ was defined as CIN (Cervical Intraepithelial Neoplasia) grades 1,2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at Month 6 in the primary study.","timeFrame":"Up to year 8"},{"measure":"Number of Subjects With Histopathologically Confirmed CIN1+ Associated With Oncogenic HPV Types Detected Within the Lesional Component of the Cervical Tissue Specimen","description":"CIN1+ was defined as CIN grades 1,2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer.\n\nOncogenic HPV types assessed included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at Month 6 in the primary study.","timeFrame":"Up to year 8"},{"measure":"Number of Subjects With Histopathologically Confirmed CIN1+ Associated With Individual Oncogenic Non-Vaccine HPV Types Detected Within the Lesional Component of the Cervical Tissue Specimen","description":"CIN1+ was defined as CIN grades 1,2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer.\n\nOncogenic HPV types assessed included HPV-31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies and were DNA negative for the corresponding HPV type at Month 6 in the primary study.","timeFrame":"Up to year 8"},{"measure":"Number of Subjects With Histopathologically-confirmed CIN2+ Associated With HPV-16 or HPV-18 Detected Within the Lesional Component of the Cervical Tissue Specimen","description":"CIN2+ was defined as CIN grades 2 and 3, AIS and invasive cervical cancer.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at Month 6 in the primary study.","timeFrame":"Up to year 8"},{"measure":"Number of Subjects With Histopathologically Confirmed CIN2+ Associated With Oncogenic HPV Types Detected Within the Lesional Component of the Cervical Tissue Specimen","description":"CIN2+ was defined as CIN grades 2 and 3, AIS and invasive cervical cancer.\n\nOncogenic HPV types assessed included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at Month 6 in the primary study.","timeFrame":"Up to year 8"},{"measure":"Number of Subjects With Histopathologically Confirmed CIN2+ Associated With Individual Oncogenic Non-Vaccine HPV Types Detected Within the Lesional Component of the Cervical Tissue Specimen","description":"CIN2+ was defined as CIN grades 2 and 3, AIS and invasive cervical cancer.\n\nOncogenic HPV types assessed included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies. and were DNA negative for the corresponding HPV type at Month 6 in the primary study.","timeFrame":"Up to year 8"},{"measure":"Number of Subjects With Abnormal Cytology Greater Than or Equal to Atypical Squamous Cells of Undetermined Significance (ASC-US) Associated With an HPV 16 and/or HPV-18 Cervical Infection","description":"Abnormal cytology included atypical squamus cells of undetermined significance (ASC-US), low-grade squamous intraepithelial lesion (LSIL), high-grade squamous intraepithelial lesion (HSIL), atypical glandular cells (AGC), atypical squamus cells and cannot exclude HSIL (ASC-H).\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at Month 6 in the primary study.","timeFrame":"Up to year 8"},{"measure":"Number of Subjects With Abnormal Cytology Greater Than or Equal to Atypical Squamous Cells of Undetermined Significance (ASC-US) Associated With Oncogenic HPV Types Cervical Infection","description":"Abnormal cytology included ASC-US, LSIL, HSIL, AGC, and ASC-H.\n\nOncogenic HPV types assessed included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at Month 6 in the primary study.","timeFrame":"Up to year 8"},{"measure":"Number of Subjects With Abnormal Cytology Greater Than or Equal to Atypical Squamous Cells of Undetermined Significance (ASC-US) Associated With Individual Oncogenic Non-vaccine HPV Types Cervical Infection","description":"Abnormal cytology included ASC-US, LSIL, HSIL, AGC and ASC-H.\n\nOncogenic HPV types assessed included HPV-31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies and were DNA negative for the corresponding HPV type at month 6 in the primary study.","timeFrame":"Up to year 8"},{"measure":"Number of Subjects With Abnormal Cytology Greater Than or Equal to Low-grade Squamous Intraepithelial Lesion (LSIL) Associated With an HPV 16 and/or HPV-18 Cervical Infection","description":"Abnormal cytology included ASC-US, LSIL, HSIL, AGC and ASC-H.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at Month 6 in the primary study.","timeFrame":"Up to year 8"},{"measure":"Number of Subjects With Abnormal Cytology Greater Than or Equal to Low-grade Squamous Intraepithelial Lesion (LSIL) Associated With Oncogenic HPV Types Cervical Infection","description":"Abnormal cytology included ASC-US, LSIL, HSIL, AGC, and ASC-H.\n\nOncogenic HPV types assessed included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at Month 6 in the primary study.","timeFrame":"Up to year 8"},{"measure":"Number of Subjects With Abnormal Cytology Greater Than or Equal to Low-grade Squamous Intraepithelial Lesion (LSIL) Associated With Individual Oncogenic Non-vaccine HPV Types Cervical Infection","description":"Abnormal cytology included ASC-US, LSIL, HSIL, AGC and ASC-H.\n\nOncogenic HPV types assessed included HPV-31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies and were DNA negative for the corresponding HPV type at month 6 in the primary study.","timeFrame":"Up to year 8"},{"measure":"Anti-HPV-16 and Anti-HPV-18 Enzyme-linked Immunosorbent Assay (ELISA) Titers in the Immunogenicity Cohort","description":"Titers are given as Geometric Mean Titers (GMTs) expressed as ELISA Units per milliliter (EL.U/mL).","timeFrame":"At Months 77-101"},{"measure":"Anti-HPV-16 and Anti-HPV-18 Pseudovirion-based Neutralization Assay (PBNA) Titers in the Immunogenicity Subset","description":"Data are expressed as Geometric Mean Titers (GMTs). The titer is the serum dilution giving a 50 percent reduction of the signal compared to a control without serum","timeFrame":"At Months 77-101"},{"measure":"Number of Subjects With New Onset Chronic Diseases (NOCD) up to Year 7","description":"NOCDs include for example asthma, type I diabetes, allergies, ...","timeFrame":"Up to year 7"},{"measure":"Number of Subjects With NOCD up to Year 8","description":"NOCDs included for example asthma, type I diabetes, allergies, ...\n\nNOCDs which were not unblinded at the subject level at the time of the analysis are not presented and will be disclosed as soon as they become available.","timeFrame":"Up to year 8"},{"measure":"Number of Subjects With New Onset Autoimmune Disease (NOAD) up to Year 7","timeFrame":"Up to year 7"},{"measure":"Number of Subjects With NOAD up to Year 8","description":"The values of NOADs are not yet corresponding to the values in each group. The cases are still blinded. They will be disclosed as soon as the results will be available.","timeFrame":"Up to year 8"},{"measure":"Number of Subjects With Medically Significant Conditions up to Year 7","description":"Medically significant conditions include adverse events (AEs) prompting emergency room or physician visits that are not related to common diseases or routine visits for physical examination or vaccination, or serious adverse events (SAEs) that are not related to common diseases. Common diseases include upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervico-vaginal yeast infections, menstrual cycle abnormalities and injury.\n\nMedically significant conditions which were not unblinded at the time of the analysis are not presented yet.","timeFrame":"Up to year 7"},{"measure":"Number of Subjects With Medically Significant Conditions up to Year 8","description":"Medically significant conditions include adverse events (AEs) prompting emergency room or physician visits that are not related to common diseases or routine visits for physical examination or vaccination, or serious adverse events (SAEs) that are not related to common diseases. Common diseases include upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervico-vaginal yeast infections, menstrual cycle abnormalities and injury.\n\nMedically significant conditions which were not unblinded at the time of the analysis are not presented yet.","timeFrame":"up to year 8"},{"measure":"Number of Subjects With Serious Adverse Events (SAEs) up to Year 7","description":"SAEs assessed include medical occurrences that result in death, is life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject","timeFrame":"Up to year 7"},{"measure":"Number of Subjects With SAEs up to Year 8","description":"SAEs assessed include medical occurrences that result in death, is life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject","timeFrame":"up to year 8"},{"measure":"Number of Subjects Presenting Cervical Infections With Any Oncogenic HPV Type.","description":"Oncogenic HPV types included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had a normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at month 6 in the primary study.","timeFrame":"Up to year 9"},{"measure":"Number of Subjects Presenting Cervical Infections With Individual Oncogenic Non-vaccine HPV Type","description":"Oncogenic types included HPV-31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies and were DNA negative for the corresponding HPV type at month 6 in the primary study.","timeFrame":"Up to year 9"},{"measure":"Number of Subjects With Persistent Infection (6-month Definition) With HPV-16 and/or HPV-18","description":"Persistent cervical HPV infection (6-month definition) was defined as detection of the same HPV type in cervical specimens at 2 consecutive evaluations over a minimum of 5 months.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had a normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at month 6 in the primary study","timeFrame":"Up to year 9"},{"measure":"Number of Subjects With Persistent Infection (6-month Definition) With Any Oncogenic HPV Type","description":"Oncogenic HPV types included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nPersistent cervical HPV infection (6-month definition) was defined as detection of the same HPV type in cervical specimens at 2 consecutive evaluations over a minimum of 5 months.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had a normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at month 6 in the primary study.","timeFrame":"Up to year 9"},{"measure":"Number of Subjects With Persistent Infection (6-month Definition) With Individual Oncogenic Non-vaccine HPV Types","description":"Oncogenic HPV types included HPV-31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nPersistent cervical HPV infection (6-month definition) was defined as detection of the same HPV type in cervical specimens at 2 consecutive evaluations over a minimum of 5 months.\n\nSubjects with an event did not report the same event during the earlier studies. Subjects with an event were DNA negative for the corresponding HPV type at Month 6 in the primary study.","timeFrame":"Up to year 9"},{"measure":"Number of Subjects With Persistent Infection (12-month Definition) With HPV-16 and/or HPV-18","description":"Persistent cervical HPV infection (12-month definition) was defined as detection of the same HPV type in cervical specimens at all consecutive evaluations over a minimum of 10 months.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had a normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at month 6 in the primary study","timeFrame":"Up to year 9"},{"measure":"Number of Subjects With Persistent Infection (12-month Definition) With Any Oncogenic HPV Types","description":"Oncogenic HPV types included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nPersistent cervical HPV infection (12-month definition) was defined as detection of the same HPV type in cervical specimens at all consecutive evaluations over a minimum of 10 months.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had a normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at month 6 in the primary study.","timeFrame":"Up to year 9"},{"measure":"Number of Subjects With Persistent Infection (12-month Definition) With Individual Oncogenic Non-vaccine HPV Types","description":"Individual oncogenic non-vaccine HPV types include HPV-31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nPersistent cervical HPV infection (12-month definition) was defined as detection of the same HPV type in cervical specimens at all consecutive evaluations over a minimum of 10 months.\n\nSubjects with an event did not report the same event in the earlier studies and were DNA negative for the corresponding HPV type at month 6 in the primary study","timeFrame":"Up to year 9"},{"measure":"Number of Subjects With Histopathologically-confirmed CIN1+ Associated With HPV-16 or HPV-18 Detected Within the Lesional Component of the Cervical Tissue Specimen","description":"Cervical Intraepithelial Neoplasia (CIN1)+ was defined as CIN grades 1,2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at Month 6 in the primary study.","timeFrame":"Up to year 9"},{"measure":"Number of Subjects With Histopathologically Confirmed CIN1+ Associated With Oncogenic HPV Types Detected Within the Lesional Component of the Cervical Tissue Specimen","description":"CIN1+ was defined as CIN grades 1,2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer.\n\nOncogenic HPV types assessed included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at Month 6 in the primary study.","timeFrame":"Up to year 9"},{"measure":"Number of Subjects With Histopathologically Confirmed CIN1+ Associated With Individual Oncogenic Non-Vaccine HPV Types Detected Within the Lesional Component of the Cervical Tissue Specimen","description":"CIN1+ was defined as CIN grades 1,2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer.\n\nOncogenic HPV types assessed included HPV-31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies and were DNA negative for the corresponding HPV type at Month 6 in the primary study.","timeFrame":"Up to year 9"},{"measure":"Number of Subjects With Histopathologically-confirmed CIN2+ Associated With HPV-16 or HPV-18 Detected Within the Lesional Component of the Cervical Tissue Specimen","description":"CIN2+ was defined as CIN grades 2 and 3, AIS and invasive cervical cancer.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at Month 6 in the primary study.","timeFrame":"Up to year 9"},{"measure":"Number of Subjects With Histopathologically Confirmed CIN2+ Associated With Oncogenic HPV Types Detected Within the Lesional Component of the Cervical Tissue Specimen","description":"CIN2+ was defined as CIN grades 2 and 3, AIS and invasive cervical cancer.\n\nOncogenic HPV types assessed included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at Month 6 in the primary study.","timeFrame":"Up to year 9"},{"measure":"Number of Subjects With Histopathologically Confirmed CIN2+ Associated With Individual Oncogenic Non-Vaccine HPV Types Detected Within the Lesional Component of the Cervical Tissue Specimen","description":"CIN2+ was defined as CIN grades 2 and 3, AIS and invasive cervical cancer.\n\nOncogenic HPV types assessed included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies and were DNA negative for the corresponding HPV type at Month 6 in the primary study.","timeFrame":"Up to year 9"},{"measure":"Number of Subjects With Abnormal Cytology Greater Than or Equal to Atypical Squamous Cells of Undertermined Significance (ASC-US) Associated With an HPV 16 and/or HPV-18 Cervical Infection","description":"Abnormal cytology included atypical squamus cells of undetermined significance (ASC-US), low-grade squamous intraepithelial lesion (LSIL), high-grade squamous intraepithelial lesion (HSIL), atypical glandular cells (AGC), atypical squamus cells and cannot exclude HSIL (ASC-H).\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at Month 6 in the primary study","timeFrame":"Up to year 9"},{"measure":"Number of Subjects With Abnormal Cytology Greater Than or Equal to Atypical Squamous Cells of Undertermined Significance (ASC-US) Associated With Oncogenic HPV Types Cervical Infection","description":"Abnormal cytology included ASC-US, LSIL, HSIL, AGC, and ASC-H.\n\nOncogenic HPV types assessed included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at Month 6 in the primary study.","timeFrame":"Up to year 9"},{"measure":"Number of Subjects With Abnormal Cytology Greater Than or Equal to Atypical Squamous Cells of Undertermined Significance (ASC-US) Associated With Individual Oncogenic Non-vaccine HPV Types Cervical Infection","description":"Abnormal cytology included ASC-US, LSIL, HSIL, AGC and ASC-H.\n\nOncogenic HPV types assessed included HPV-31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies and were DNA negative for the corresponding HPV type at month 6 in the primary study","timeFrame":"Up to year 9"},{"measure":"Number of Subjects With Abnormal Cytology Greater Than or Equal to Low-grade Squamous Intraepithelial Lesion (LSIL) Associated With an HPV 16 and/or HPV-18 Cervical Infection","description":"Abnormal cytology included ASC-US, LSIL, HSIL, AGC and ASC-H.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at Month 6 in the primary study.","timeFrame":"Up to year 9"},{"measure":"Number of Subjects With Abnormal Cytology Greater Than or Equal to Low-grade Squamous Intraepithelial Lesion (LSIL) Associated With Oncogenic HPV Types Cervical Infection","description":"Abnormal cytology included ASC-US, LSIL, HSIL, AGC, and ASC-H.\n\nOncogenic HPV types assessed included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at Month 6 in the primary study.","timeFrame":"Up to year 9"},{"measure":"Number of Subjects With Abnormal Cytology Greater Than or Equal to Low-grade Squamous Intraepithelial Lesion (LSIL) Associated With Individual Oncogenic Non-vaccine HPV Types Cervical Infection","description":"Abnormal cytology included ASC-US, LSIL, HSIL, AGC and ASC-H.\n\nOncogenic HPV types assessed included HPV-31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies and were DNA negative for the corresponding HPV type at month 6 in the primary study.","timeFrame":"Up to year 9"},{"measure":"Anti-HPV-16 and Anti-HPV-18 Enzyme-linked Immunosorbent Assay (ELISA) Titers in the Immunogenicity Cohort","description":"Titers are given as Geometric Mean Titers (GMTs) expressed as Enzyme-linked immunosorbent assay (ELISA) Units per milliliter (EL.U/mL).\n\nThe cut-off-vales assessed were \\>= 8 or 7 EL. U/mL for anti-HPV-16 and 18, respectively.","timeFrame":"At Month 77 until year 9 (Month 113)"},{"measure":"Anti-HPV-16 and Anti-HPV-18 Pseudovirion-based Neutralization Assay (PBNA) Titers in the Immunogenicity Subset","description":"Data are expressed as Geometric Mean Titers (GMTs). The titer is the serum dilution giving a 50 percent reduction of the signal compared to a control without serum","timeFrame":"At Month 77 until year 9 (Month 113)"},{"measure":"Number of Subjects With New Onset Chronic Diseases (NOCD) up to Year 9","description":"NOCDs include for example asthma, type I diabetes, allergies, ...","timeFrame":"Up to year 9"},{"measure":"Number of Subjects With New Onset Autoimmune Disease (NOAD) up to Year 9.","timeFrame":"Up to year 9"},{"measure":"Number of Subjects With Medically Signifant Conditions up to Year 9","description":"Medically significant conditions include adverse events (AEs) prompting emergency room or physician visits that are not related to common diseases or routine visits for physical examination or vaccination, or serious adverse events (SAEs) that are not related to common diseases. Common diseases include upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervico-vaginal yeast infections, menstrual cycle abnormalities and injury.","timeFrame":"Up to year 9"},{"measure":"Number of Subjects With Serious Adverse Events (SAEs) up to Year 9.","description":"SAEs assessed include medical occurrences that result in death, is life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject","timeFrame":"up to year 9"},{"measure":"Number of Subjects Presenting Cervical Infections With Any Oncogenic HPV Type.","description":"Oncogenic HPV types included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had a normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at month 6 in the primary study.","timeFrame":"Up to year 7"},{"measure":"Number of Subjects Presenting Cervical Infections With Individual Oncogenic Non-vaccine HPV Type.","description":"Oncogenic types included HPV-31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies and were DNA negative for the corresponding HPV type at month 6 in the primary study.","timeFrame":"Up to year 7"},{"measure":"Number of Subjects With Persistent Infection (6-month Definition) With HPV-16 and/or HPV-18","description":"Persistent cervical HPV infection (6-month definition) was defined as detection of the same HPV type in cervical specimens at 2 consecutive evaluations over a minimum of 5 months.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had a normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at month 6 in the primary study","timeFrame":"Up to year 7"},{"measure":"Number of Subjects With Persistent Infection (6-month Definition) With Any Oncogenic HPV Type","description":"Oncogenic HPV types included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nPersistent cervical HPV infection (6-month definition) was defined as detection of the same HPV type in cervical specimens at 2 consecutive evaluations over a minimum of 5 months.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had a normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at month 6 in the primary study.","timeFrame":"Up to year 7"},{"measure":"Number of Subjects With Persistent Infection (6-month Definition) With Individual Oncogenic Non-vaccine HPV Types","description":"Oncogenic HPV types included HPV-31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nPersistent cervical HPV infection (6-month definition) was defined as detection of the same HPV type in cervical specimens at 2 consecutive evaluations over a minimum of 5 months.\n\nSubjects with an event did not report the same event during the earlier studies. Subjects with an event were DNA negative for the corresponding HPV type at Month 6 in the primary study.","timeFrame":"Up to year 7"},{"measure":"Number of Subjects With Persistent Infection (12-month Definition) With HPV-16 and/or HPV-18","description":"Persistent cervical HPV infection (12-month definition) was defined as detection of the same HPV type in cervical specimens at all consecutive evaluations over a minimum of 10 months.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had a normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at month 6 in the primary study.","timeFrame":"Up to year 7"},{"measure":"Number of Subjects With Persistent Infection (12-month Definition) With Any Oncogenic HPV Type","description":"Oncogenic HPV types included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nPersistent cervical HPV infection (12-month definition) was defined as detection of the same HPV type in cervical specimens at all consecutive evaluations over a minimum of 10 months.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had a normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at month 6 in the primary study.","timeFrame":"Up to year 7"},{"measure":"Number of Subjects With Persistent Infection (12-month Definition) With Individual Oncogenic Non-vaccine HPV Types","description":"Individual oncogenic non-vaccine HPV types include HPV-31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nPersistent cervical HPV infection (12-month definition) was defined as detection of the same HPV type in cervical specimens at all consecutive evaluations over a minimum of 10 months.\n\nSubjects with an event did not report the same event in the earlier studies and were DNA negative for the corresponding HPV type at month 6 in the primary study.","timeFrame":"Up to year 7"},{"measure":"Number of Subjects With Histopathologically-confirmed CIN1+ Associated With HPV-16 or HPV-18 Detected Within the Lesional Component of the Cervical Tissue Specimen","description":"CIN1+ was defined as CIN grades 1,2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at Month 6 in the primary study.","timeFrame":"Up to year 7"},{"measure":"Number of Subjects With Histopathologically Confirmed CIN1+ Associated With Oncogenic HPV Types Detected Within the Lesional Component of the Cervical Tissue Specimen","description":"CIN1+ was defined as CIN grades 1,2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer.\n\nOncogenic HPV types assessed included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at Month 6 in the primary study.","timeFrame":"Up to year 7"},{"measure":"Number of Subjects With Histopathologically Confirmed CIN1+ Associated With Individual Oncogenic Non-Vaccine HPV Types Detected Within the Lesional Component of the Cervical Tissue Specimen","description":"CIN1+ was defined as CIN grades 1,2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer.\n\nOncogenic HPV types assessed included HPV-31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies and were DNA negative for the corresponding HPV type at Month 6 in the primary study.","timeFrame":"Up to year 7"},{"measure":"Number of Subjects With Histopathologically-confirmed CIN2+ Associated With HPV-16 or HPV-18 Detected Within the Lesional Component of the Cervical Tissue Specimen","description":"CIN2+ was defined as CIN grades 2 and 3, AIS and invasive cervical cancer.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at Month 6 in the primary study.","timeFrame":"Up to year 7"},{"measure":"Number of Subjects With Histopathologically Confirmed CIN2+ Associated With Oncogenic HPV Types Detected Within the Lesional Component of the Cervical Tissue Specimen","description":"CIN2+ was defined as CIN grades 2 and 3, AIS and invasive cervical cancer.\n\nOncogenic HPV types assessed included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at Month 6 in the primary study.","timeFrame":"Up to year 7"},{"measure":"Number of Subjects With Histopathologically Confirmed CIN2+ Associated With Individual Oncogenic Non-Vaccine HPV Types Detected Within the Lesional Component of the Cervical Tissue Specimen","description":"CIN2+ was defined as CIN grades 2 and 3, AIS and invasive cervical cancer.\n\nOncogenic HPV types assessed included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies and were DNA negative for the corresponding HPV type at Month 6 in the primary study.","timeFrame":"Up to year 7"},{"measure":"Number of Subjects With Abnormal Cytology Greater Than or Equal to Atypical Squamous Cells of Undetermined Significance (ASC-US) Associated With an HPV 16 and/or HPV-18 Cervical Infection","description":"Abnormal cytology included atypical squamus cells of undetermined significance (ASC-US), low-grade squamous intraepithelial lesion (LSIL), high-grade squamous intraepithelial lesion (HSIL), atypical glandular cells (AGC), atypical squamus cells and cannot exclude HSIL (ASC-H).\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at Month 6 in the primary study.","timeFrame":"Up to year 7"},{"measure":"Number of Subjects With Abnormal Cytology Greater Than or Equal to Atypical Squamous Cells of Undetermined Significance (ASC-US) Associated With Oncogenic HPV Types Cervical Infection","description":"Abnormal cytology included ASC-US, LSIL, HSIL, AGC, and ASC-H.\n\nOncogenic HPV types assessed included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at Month 6 in the primary study.","timeFrame":"Up to year 7"},{"measure":"Number of Subjects With Abnormal Cytology Greater Than or Equal to Atypical Squamous Cells of Undetermined Significance (ASC-US) Associated With Individual Oncogenic Non-vaccine HPV Types Cervical Infection","description":"Abnormal cytology included ASC-US, LSIL, HSIL, AGC and ASC-H.\n\nOncogenic HPV types assessed included HPV-31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies and were DNA negative for the corresponding HPV type at month 6 in the primary study.","timeFrame":"Up to year 7"},{"measure":"Number of Subjects With Abnormal Cytology Greater Than or Equal to Low-grade Squamous Intraepithelial Lesion (LSIL) Associated With an HPV 16 and/or HPV-18 Cervical Infection","description":"Abnormal cytology included ASC-US, LSIL, HSIL, AGC and ASC-H.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at Month 6 in the primary study.","timeFrame":"Up to year 7"},{"measure":"Number of Subjects With Abnormal Cytology Greater Than or Equal to Low-grade Squamous Intraepithelial Lesion (LSIL) Associated With Oncogenic HPV Types Cervical Infection","description":"Abnormal cytology included ASC-US, LSIL, HSIL, AGC, and ASC-H.\n\nOncogenic HPV types assessed included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at Month 6 in the primary study.","timeFrame":"Up to year 7"},{"measure":"Number of Subjects With Abnormal Cytology Greater Than or Equal to Low-grade Squamous Intraepithelial Lesion (LSIL) Associated With Individual Oncogenic Non-vaccine HPV Types Cervical Infection","description":"Abnormal cytology included ASC-US, LSIL, HSIL, AGC and ASC-H.\n\nOncogenic HPV types assessed included HPV-31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies and were DNA negative for the corresponding HPV type at month 6 in the primary study.","timeFrame":"Up to year 7"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study.\n* Subjects who participated in study 580299-007.\n* Written informed consent obtained from the subject prior to enrollment.\n\nExclusion Criteria:\n\n* Use or planned use of any investigational or non-registered product other than the study vaccine.\n* Decoding of the subject's 580299-001 treatment allocation to either the subject or the investigator.\n* Administration or planned administration of any other HPV vaccine, other than the vaccine administered in study 580299-001.","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"15 Years","maximumAge":"25 Years","stdAges":["CHILD","ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"GSK Clinical Trials","affiliation":"GlaxoSmithKline","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"GSK Investigational Site","city":"Curitiba","state":"Paraná","zip":"80069-900","country":"Brazil","geoPoint":{"lat":-25.42778,"lon":-49.27306}},{"facility":"GSK Investigational Site","city":"Porto Alegre","state":"Rio Grande do Sul","zip":"90035-903","country":"Brazil","geoPoint":{"lat":-30.03283,"lon":-51.23019}},{"facility":"GSK Investigational Site","city":"São Paulo","state":"São Paulo","zip":"03015000","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}},{"facility":"GSK Investigational Site","city":"Campinas","zip":"13083-970","country":"Brazil","geoPoint":{"lat":-22.90556,"lon":-47.06083}},{"facility":"GSK Investigational Site","city":"Fortaleza","country":"Brazil","geoPoint":{"lat":-3.71722,"lon":-38.54306}}]},"referencesModule":{"references":[{"pmid":"25424918","type":"DERIVED","citation":"Naud PS, Roteli-Martins CM, De Carvalho NS, Teixeira JC, de Borba PC, Sanchez N, Zahaf T, Catteau G, Geeraerts B, Descamps D. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Hum Vaccin Immunother. 2014;10(8):2147-62. doi: 10.4161/hv.29532."},{"pmid":"22327492","type":"DERIVED","citation":"Roteli-Martins CM, Naud P, De Borba P, Teixeira JC, De Carvalho NS, Zahaf T, Sanchez N, Geeraerts B, Descamps D. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up. Hum Vaccin Immunother. 2012 Mar;8(3):390-7. doi: 10.4161/hv.18865. Epub 2012 Feb 13."}],"seeAlsoLinks":[{"label":"Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.","url":"https://www.clinicalstudydatarequest.com"}],"availIpds":[{"id":"109616 (Y7)","type":"Study Protocol","url":"https://www.clinicalstudydatarequest.com","comment":"For additional information about this study please refer to the GSK Clinical Study Register"},{"id":"109616 (Y7)","type":"Clinical Study Report","url":"https://www.clinicalstudydatarequest.com","comment":"For additional information about this study please refer to the GSK Clinical Study Register"},{"id":"109616 (Y7)","type":"Individual Participant Data Set","url":"https://www.clinicalstudydatarequest.com","comment":"For additional information about this study please refer to the GSK Clinical Study Register. The results of this study 109624 are summarised with studies 109616 and 109625 on the GSK Clinical Study Register."},{"id":"109616 (Y7)","type":"Informed Consent Form","url":"https://www.clinicalstudydatarequest.com","comment":"For additional information about this study please refer to the GSK Clinical Study Register"},{"id":"109616 (Y7)","type":"Dataset Specification","url":"https://www.clinicalstudydatarequest.com","comment":"For additional information about this study please refer to the GSK Clinical Study Register"},{"id":"109616 (Y7)","type":"Statistical Analysis Plan","url":"https://www.clinicalstudydatarequest.com","comment":"For additional information about this study please refer to the GSK Clinical Study Register"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site."}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Out of the five subjects withdraw at Year 7, three subjects came back during Year 8 and are therefore not longer considered as withdraw subjects. At Year 9, one subject, who did not participate to Year 7 and Year 8 visits, came back for one of the visits and was added to Total cohort.","groups":[{"id":"FG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"FG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"periods":[{"title":"Year 7","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"222"},{"groupId":"FG001","numSubjects":"211"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"220"},{"groupId":"FG001","numSubjects":"208"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"3"}]}],"dropWithdraws":[{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Could not attend in time","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"3"}]}]},{"title":"Year 8","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","comment":"1 subject withdrawn at Year 7 came back and was therefore no longer considered as withdrawn.","numSubjects":"223"},{"groupId":"FG001","comment":"2 subjects withdrawn at Year 7 came back and were therefore no longer considered as withdrawn.","numSubjects":"213"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"222"},{"groupId":"FG001","numSubjects":"211"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"}]}],"dropWithdraws":[{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Could not attend in time","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]}]},{"title":"Year 9","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","comment":"1 subject did not particpate at the previous timepoint, came back and was added in the Total cohort","numSubjects":"224"},{"groupId":"FG001","numSubjects":"213"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"219"},{"groupId":"FG001","numSubjects":"212"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"1"}]}],"dropWithdraws":[{"type":"Migrated/moved from study area","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Personal reasons","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"BG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"222"},{"groupId":"BG001","value":"211"},{"groupId":"BG002","value":"433"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"26.5","spread":"3.2"},{"groupId":"BG001","value":"26.4","spread":"2.9"},{"groupId":"BG002","value":"26.5","spread":"3.05"}]}]}]},{"title":"Gender","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"222"},{"groupId":"BG001","value":"211"},{"groupId":"BG002","value":"433"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects Presenting Cervical Infections With Human Papillomavirus (HPV) -16 and/or HPV-18","description":"Cervical HPV infection was defined as the first detection of an HPV type in a subject previously negative for that HPV type.","populationDescription":"According-To-Protocol (ATP) cohort for analysis of efficacy included all subjects for whom differential treatment effect on efficacy was likely (i.e. who met all eligibility criteria in the primary study (580299/001), the first follow-up (580299/007) and the current study), who complied with the protocol and for whom efficacy data were available.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"subjects","timeFrame":"Up to year 8","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"178"},{"groupId":"OG001","value":"139"}]}],"classes":[{"title":"HPV-16 (N=176;122)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5"}]}]},{"title":"HPV-18 (N=178;133)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"}]}]},{"title":"HPV-16/18 (N=176;139)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Presenting Cervical Infections With Any Oncogenic HPV Type","description":"Oncogenic HPV types included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had a normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at month 6 in the primary study.","populationDescription":"The ATP cohort for analysis of efficacy included all subjects for whom differential treatment effect on efficacy was likely (i.e. who met all eligibility criteria in the primary study (580299/001), the first follow-up (580299/007) and the current study), who complied with the protocol and for whom efficacy data were available.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"subjects","timeFrame":"Up to year 8","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"154"},{"groupId":"OG001","value":"135"}]}],"classes":[{"title":"Including HPV-16 or 18 (N=154; 133)","categories":[{"measurements":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"39"}]}]},{"title":"Without HPV-16 or 18 (N=154; 135)","categories":[{"measurements":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"36"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Presenting Cervical Infections With Individual Oncogenic Non-vaccine HPV Type","description":"Oncogenic types included HPV-31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies and were DNA negative for the corresponding HPV type at month 6 in the primary study.","populationDescription":"The ATP cohort for analysis of efficacy included all subjects for whom differential treatment effect on efficacy was likely (i.e. who met all eligibility criteria in the primary study (580299/001), the first follow-up (580299/007) and the current study), who complied with the protocol and for whom efficacy data were available.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"subjects","timeFrame":"Up to year 8","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"201"},{"groupId":"OG001","value":"180"}]}],"classes":[{"title":"HPV-31 (N=195; 168)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"5"}]}]},{"title":"HPV-33 (N=195; 175)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-35 (N=195; 177)","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"}]}]},{"title":"HPV-39 (N=189; 162)","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"}]}]},{"title":"HPV-45 (N=201; 174)","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"}]}]},{"title":"HPV-51 (N=166; 152)","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"10"}]}]},{"title":"HPV-52 (N=170; 152)","categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"9"}]}]},{"title":"HPV-56 (N=181; 168)","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"}]}]},{"title":"HPV-58 (N=189; 173)","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"}]}]},{"title":"HPV-59 (N=193; 180)","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-66 (N= 176; 164)","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"8"}]}]},{"title":"HPV-68 (N= 186; 166)","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Persistent Infection (6-month Definition) With HPV-16 and/or HPV-18","description":"Persistent cervical HPV infection (6-month definition) was defined as detection of the same HPV type in cervical specimens at 2 consecutive evaluations over a minimum of 5 months.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had a normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at month 6 in the primary study.","populationDescription":"The ATP cohort for analysis of efficacy included all subjects for whom differential treatment effect on efficacy was likely (i.e. who met all eligibility criteria in the primary study (580299/001), the first follow-up (580299/007) and the current study), who complied with the protocol and for whom efficacy data were available.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"subjects","timeFrame":"Up to year 8","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"178"},{"groupId":"OG001","value":"151"}]}],"classes":[{"title":"HPV-16/18 (N=178; 144)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-16 (N=178; 149)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-18 (N=178;151)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Persistent Infection (6-month Definition) With Any Oncogenic HPV Types","description":"Oncogenic HPV types included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nPersistent cervical HPV infection (6-month definition) was defined as detection of the same HPV type in cervical specimens at 2 consecutive evaluations over a minimum of 5 months.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had a normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at month 6 in the primary study.","populationDescription":"The ATP cohort for analysis of efficacy included all subjects for whom differential treatment effect on efficacy was likely (i.e. who met all eligibility criteria in the primary study (580299/001), the first follow-up (580299/007) and the current study), who complied with the protocol and for whom efficacy data were available.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"subjects","timeFrame":"Up to year 8","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"162"},{"groupId":"OG001","value":"143"}]}],"classes":[{"title":"Including HPV-16 or 18 (N=162; 142)","categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"17"}]}]},{"title":"Without HPV-16 or 18 (N=162; 143)","categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"17"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Persistent Infection (6-month Definition) With Individual Oncogenic Non-vaccine HPV Types","description":"Oncogenic HPV types included HPV-31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nPersistent cervical HPV infection (6-month definition) was defined as detection of the same HPV type in cervical specimens at 2 consecutive evaluations over a minimum of 5 months.\n\nSubjects with an event did not report the same event during the earlier studies. Subjects with an event were DNA negative for the corresponding HPV type at Month 6 in the primary study.","populationDescription":"The ATP cohort for analysis of efficacy included all subjects for whom differential treatment effect on efficacy was likely (i.e. who met all eligibility criteria in the primary study (580299/001), the first follow-up (580299/007) and the current study), who complied with the protocol and for whom efficacy data were available.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"Up to year 8","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"203"},{"groupId":"OG001","value":"184"}]}],"classes":[{"title":"HPV-31 (N= 201; 180)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"}]}]},{"title":"HPV-33 (N= 199; 182)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-35 (N= 200; 180)","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"}]}]},{"title":"HPV-39 (N= 199; 174)","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}]},{"title":"HPV-45 (N= 203; 184)","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-51 (N= 191; 174)","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}]},{"title":"HPV-52 (N= 185; 166)","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"}]}]},{"title":"HPV-56 (N= 196; 182)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}]}]},{"title":"HPV-58 (N= 195; 181)","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}]},{"title":"HPV-59 (N=202; 184)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-66 (N= 191; 171)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}]}]},{"title":"HPV-68 (N= 199; 181)","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Persistent Infection (12-month Definition) With HPV-16 and/or HPV-18","description":"Persistent cervical HPV infection (12-month definition) was defined as detection of the same HPV type in cervical specimens at all consecutive evaluations over a minimum of 10 months.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had a normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at month 6 in the primary study.","populationDescription":"The ATP cohort for analysis of efficacy included all subjects for whom differential treatment effect on efficacy was likely (i.e. who met all eligibility criteria in the primary study (580299/001), the first follow-up (580299/007) and the current study), who complied with the protocol and for whom efficacy data were available.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"subjects","timeFrame":"Up to year 8","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"178"},{"groupId":"OG001","value":"156"}]}],"classes":[{"title":"HPV-16/18 (N= 178; 152)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-16 (N= 178; 154)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-18 (N= 178; 156)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Persistent Infection (12-month Definition) With Any Oncogenic HPV Types","description":"Oncogenic HPV types included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nPersistent cervical HPV infection (12-month definition) was defined as detection of the same HPV type in cervical specimens at all consecutive evaluations over a minimum of 10 months.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had a normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at month 6 in the primary study.","populationDescription":"The ATP cohort for analysis of efficacy included all subjects for whom differential treatment effect on efficacy was likely (i.e. who met all eligibility criteria in the primary study (580299/001), the first follow-up (580299/007) and the current study), who complied with the protocol and for whom efficacy data were available.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"subjects","timeFrame":"Up to year 8","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"143"}]}],"classes":[{"title":"Including HPV-16 or 18 (N= 163; 142)","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"3"}]}]},{"title":"Without HPV-16 or 18 (N= 163; 143)","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"3"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Persistent Infection (12-month Definition) With Individual Oncogenic Non-vaccine HPV Types","description":"Individual oncogenic non-vaccine HPV types include HPV-31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nPersistent cervical HPV infection (12-month definition) was defined as detection of the same HPV type in cervical specimens at all consecutive evaluations over a minimum of 10 months.\n\nSubjects with an event did not report the same event in the earlier studies and were DNA negative for the corresponding HPV type at month 6 in the primary study.","populationDescription":"The ATP cohort for analysis of efficacy included all subjects for whom differential treatment effect on efficacy was likely (i.e. who met all eligibility criteria in the primary study (580299/001), the first follow-up (580299/007) and the current study), who complied with the protocol and for whom efficacy data were available.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"subjects","timeFrame":"Up to year 8","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"204"},{"groupId":"OG001","value":"186"}]}],"classes":[{"title":"HPV-31 (N= 202; 181)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}]}]},{"title":"HPV-33 (N= 202; 184)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-35 (N= 200; 185)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV- 39 (N= 200; 179)","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-45 (N= 204; 186)","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV- 51 (N= 198; 182)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-52 (N= 191; 172)","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-56 (N= 200; 185)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-58 (N= 199; 183)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-59 (N= 203; 186)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-66 (N= 195; 177)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-68 (N= 200; 184)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With HPV-16 or HPV-18 Detected Within the Lesional Component of the Cervical Tissue Specimen","description":"CIN1+ was defined as CIN (Cervical Intraepithelial Neoplasia) grades 1,2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at Month 6 in the primary study.","populationDescription":"The analysis was performed on the Total Cohort, which included all enrolled subjects who came at the first visit and received at least one vaccine dose (Cervarix or placebo)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"subjects","timeFrame":"Up to year 8","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"199"},{"groupId":"OG001","value":"186"}]}],"classes":[{"title":"HPV-16/18 (N= 199; 182)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-16 (N= 199; 183)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-18 (N= 199; 186)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Histopathologically Confirmed CIN1+ Associated With Oncogenic HPV Types Detected Within the Lesional Component of the Cervical Tissue Specimen","description":"CIN1+ was defined as CIN grades 1,2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer.\n\nOncogenic HPV types assessed included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at Month 6 in the primary study.","populationDescription":"The analysis was performed on the Total Cohort, which included all enrolled subjects who came at the first visit and received at least one vaccine dose (Cervarix or placebo)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"subjects","timeFrame":"Up to year 8","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"199"},{"groupId":"OG001","value":"187"}]}],"classes":[{"title":"Including HRV-16 or 18","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Without HRV-16 or 18","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Histopathologically Confirmed CIN1+ Associated With Individual Oncogenic Non-Vaccine HPV Types Detected Within the Lesional Component of the Cervical Tissue Specimen","description":"CIN1+ was defined as CIN grades 1,2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer.\n\nOncogenic HPV types assessed included HPV-31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies and were DNA negative for the corresponding HPV type at Month 6 in the primary study.","populationDescription":"The analysis was performed on the Total Cohort, which included all enrolled subjects who came at the first visit and received at least one vaccine dose (Cervarix or placebo)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"subjects","timeFrame":"Up to year 8","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"222"},{"groupId":"OG001","value":"209"}]}],"classes":[{"title":"HPV-31 (N= 221; 207)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-33 (N= 220; 207)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-35 (N= 219; 206)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-39 (N= 222; 209)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-45 (N= 221; 208)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-51 (N= 215; 206)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-52 (N= 218; 204)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-56 (N= 219; 209)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-58 (N=221; 206)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-59 (N=220; 208)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-66 (N= 219; 203)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-68 (N= 221; 209)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Histopathologically-confirmed CIN2+ Associated With HPV-16 or HPV-18 Detected Within the Lesional Component of the Cervical Tissue Specimen","description":"CIN2+ was defined as CIN grades 2 and 3, AIS and invasive cervical cancer.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at Month 6 in the primary study.","populationDescription":"The analysis was performed on the Total Cohort, which included all enrolled subjects who came at the first visit and received at least one vaccine dose (Cervarix or placebo)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"subjects","timeFrame":"Up to year 8","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"199"},{"groupId":"OG001","value":"186"}]}],"classes":[{"title":"HPV-16/18 (N= 199; 184)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-16 (N= 199; 185)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-18 (N= 199; 186)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Histopathologically Confirmed CIN2+ Associated With Oncogenic HPV Types Detected Within the Lesional Component of the Cervical Tissue Specimen","description":"CIN2+ was defined as CIN grades 2 and 3, AIS and invasive cervical cancer.\n\nOncogenic HPV types assessed included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at Month 6 in the primary study.","populationDescription":"The analysis was performed on the Total Cohort, which included all enrolled subjects who came at the first visit and received at least one vaccine dose (Cervarix or placebo)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"subjects","timeFrame":"Up to year 8","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"199"},{"groupId":"OG001","value":"187"}]}],"classes":[{"title":"Including HPV-16 or 18","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Without HPV-16 or 18","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Histopathologically Confirmed CIN2+ Associated With Individual Oncogenic Non-Vaccine HPV Types Detected Within the Lesional Component of the Cervical Tissue Specimen","description":"CIN2+ was defined as CIN grades 2 and 3, AIS and invasive cervical cancer.\n\nOncogenic HPV types assessed included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies. and were DNA negative for the corresponding HPV type at Month 6 in the primary study.","populationDescription":"The analysis was performed on the Total Cohort, which included all enrolled subjects who came at the first visit and received at least one vaccine dose (Cervarix or placebo)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"subjects","timeFrame":"Up to year 8","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"222"},{"groupId":"OG001","value":"209"}]}],"classes":[{"title":"HPV-31 (N= 221; 208)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-33 (N= 220; 208)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-35 (N= 220; 206)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-39 (N= 222; 209)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-45 (N= 221; 208)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-51 (N= 217; 207)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-52 (N= 218; 206)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-56 (N= 219; 209)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-58 (N= 221; 207)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-59 (N= 220; 208)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-66 (N= 220; 205)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-68 (N= 221; 209)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Abnormal Cytology Greater Than or Equal to Atypical Squamous Cells of Undetermined Significance (ASC-US) Associated With an HPV 16 and/or HPV-18 Cervical Infection","description":"Abnormal cytology included atypical squamus cells of undetermined significance (ASC-US), low-grade squamous intraepithelial lesion (LSIL), high-grade squamous intraepithelial lesion (HSIL), atypical glandular cells (AGC), atypical squamus cells and cannot exclude HSIL (ASC-H).\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at Month 6 in the primary study.","populationDescription":"The analysis was performed on the Total Cohort, which included all enrolled subjects who came at the first visit and received at least one vaccine dose (Cervarix or placebo)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"subjects","timeFrame":"Up to year 8","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"199"},{"groupId":"OG001","value":"177"}]}],"classes":[{"title":"HPV-16/18 (N= 198; 165)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-16 (N= 198; 171)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-18 (N= 199; 177)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Abnormal Cytology Greater Than or Equal to Atypical Squamous Cells of Undetermined Significance (ASC-US) Associated With Oncogenic HPV Types Cervical Infection","description":"Abnormal cytology included ASC-US, LSIL, HSIL, AGC, and ASC-H.\n\nOncogenic HPV types assessed included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at Month 6 in the primary study.","populationDescription":"The analysis was performed on the Total Cohort, which included all enrolled subjects who came at the first visit and received at least one vaccine dose (Cervarix or placebo)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"subjects","timeFrame":"Up to year 8","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"196"},{"groupId":"OG001","value":"184"}]}],"classes":[{"title":"Including HPV-16 or 18 (N= 196; 183)","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"15"}]}]},{"title":"Without HPV-16 or 18 (N= 196; 184)","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"15"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Abnormal Cytology Greater Than or Equal to Atypical Squamous Cells of Undetermined Significance (ASC-US) Associated With Individual Oncogenic Non-vaccine HPV Types Cervical Infection","description":"Abnormal cytology included ASC-US, LSIL, HSIL, AGC and ASC-H.\n\nOncogenic HPV types assessed included HPV-31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies and were DNA negative for the corresponding HPV type at month 6 in the primary study.","populationDescription":"The analysis was performed on the Total Cohort, which included all enrolled subjects who came at the first visit and received at least one vaccine dose (Cervarix or placebo)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"subjects","timeFrame":"Up to year 8","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"220"},{"groupId":"OG001","value":"206"}]}],"classes":[{"title":"HPV-31 (N= 217; 200)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5"}]}]},{"title":"HPV-33 (N= 218; 202)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-35 (N= 217; 202)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-39 (N= 217; 197)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-45 (N= 220; 204)","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-51 (N= 202; 194)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"}]}]},{"title":"HPV-52 (N= 205; 183)","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}]},{"title":"HPV-56 (N= 207; 202)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-58 (N= 213; 199)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"}]}]},{"title":"HPV-59 (N= 216; 206)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-66 (N= 214; 194)","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-68 (N= 217; 202)","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Abnormal Cytology Greater Than or Equal to Low-grade Squamous Intraepithelial Lesion (LSIL) Associated With an HPV 16 and/or HPV-18 Cervical Infection","description":"Abnormal cytology included ASC-US, LSIL, HSIL, AGC and ASC-H.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at Month 6 in the primary study.","populationDescription":"The analysis was performed on the Total Cohort, which included all enrolled subjects who came at the first visit and received at least one vaccine dose (Cervarix or placebo)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"subjects","timeFrame":"Up to year 8","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"199"},{"groupId":"OG001","value":"183"}]}],"classes":[{"title":"HPV-16/18 (N= 198; 174)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-16 (N= 198; 177)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-18 (N= 199; 183)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Abnormal Cytology Greater Than or Equal to Low-grade Squamous Intraepithelial Lesion (LSIL) Associated With Oncogenic HPV Types Cervical Infection","description":"Abnormal cytology included ASC-US, LSIL, HSIL, AGC, and ASC-H.\n\nOncogenic HPV types assessed included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at Month 6 in the primary study.","populationDescription":"The analysis was performed on the Total Cohort, which included all enrolled subjects who came at the first visit and received at least one vaccine dose (Cervarix or placebo)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"subjects","timeFrame":"Up to year 8","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"186"}]}],"classes":[{"title":"Including HPV-16 or 18","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"12"}]}]},{"title":"Without HPV-16 or 18","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"12"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Abnormal Cytology Greater Than or Equal to Low-grade Squamous Intraepithelial Lesion (LSIL) Associated With Individual Oncogenic Non-vaccine HPV Types Cervical Infection","description":"Abnormal cytology included ASC-US, LSIL, HSIL, AGC and ASC-H.\n\nOncogenic HPV types assessed included HPV-31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies and were DNA negative for the corresponding HPV type at month 6 in the primary study.","populationDescription":"The analysis was performed on the Total Cohort, which included all enrolled subjects who came at the first visit and received at least one vaccine dose (Cervarix or placebo)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"subjects","timeFrame":"Up to year 8","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"220"},{"groupId":"OG001","value":"207"}]}],"classes":[{"title":"HPV-31 (N= 218; 202)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"}]}]},{"title":"HPV-33 (N= 219; 205)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-35 (N= 217; 204)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-39 (N= 219; 200)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-45 (N= 220; 205)","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-51 (N= 211; 197)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"}]}]},{"title":"HPV-52 (N= 210; 191)","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"}]}]},{"title":"HPV-56 (N= 211; 202)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-58 (N= 216; 203)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]},{"title":"HPV-59 (N= 219; 207)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-66 (N= 217; 195)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-68 (N= 219; 206)","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}]}]},{"type":"SECONDARY","title":"Anti-HPV-16 and Anti-HPV-18 Enzyme-linked Immunosorbent Assay (ELISA) Titers in the Immunogenicity Cohort","description":"Titers are given as Geometric Mean Titers (GMTs) expressed as ELISA Units per milliliter (EL.U/mL).","populationDescription":"The analyses were performed on the ATP cohort for immunogenicity, which included evaluable subjects for whom immunogenicity data were available.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"EL.U/mL","timeFrame":"At Months 77-101","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"111"},{"groupId":"OG001","value":"68"}]}],"classes":[{"title":"Anti-HPV-16 Month 77-82 (N= 69; 54)","categories":[{"measurements":[{"groupId":"OG000","value":"374.9","lowerLimit":"291.8","upperLimit":"481.8"},{"groupId":"OG001","value":"5.4","lowerLimit":"4.4","upperLimit":"6.6"}]}]},{"title":"Anti-HPV-16 Month 83-88 (N= 111; 68)","categories":[{"measurements":[{"groupId":"OG000","value":"383.4","lowerLimit":"312.9","upperLimit":"469.9"},{"groupId":"OG001","value":"5.1","lowerLimit":"4.4","upperLimit":"6.0"}]}]},{"title":"Anti-HPV-16 Month 89-94 (N= 94; 67)","categories":[{"measurements":[{"groupId":"OG000","value":"346.3","lowerLimit":"270.3","upperLimit":"443.6"},{"groupId":"OG001","value":"5.4","lowerLimit":"4.4","upperLimit":"6.7"}]}]},{"title":"Anti-HPV-16 Month 95-101 (N= 87; 56)","categories":[{"measurements":[{"groupId":"OG000","value":"435.1","lowerLimit":"347.5","upperLimit":"544.9"},{"groupId":"OG001","value":"5.4","lowerLimit":"4.4","upperLimit":"6.6"}]}]},{"title":"Anti-HPV-18 Month 77-82 (N= 69; 54)","categories":[{"measurements":[{"groupId":"OG000","value":"252.8","lowerLimit":"196.9","upperLimit":"324.7"},{"groupId":"OG001","value":"4.3","lowerLimit":"3.7","upperLimit":"5.1"}]}]},{"title":"Anti-HPV-18 Month 83-88 (N= 111; 68)","categories":[{"measurements":[{"groupId":"OG000","value":"251.0","lowerLimit":"208.7","upperLimit":"301.8"},{"groupId":"OG001","value":"5.0","lowerLimit":"4.1","upperLimit":"6.1"}]}]},{"title":"Anti-HPV-18 Month 89-94 (N= 94; 67)","categories":[{"measurements":[{"groupId":"OG000","value":"234.6","lowerLimit":"188.8","upperLimit":"291.5"},{"groupId":"OG001","value":"4.4","lowerLimit":"3.7","upperLimit":"5.2"}]}]},{"title":"Anti-HPV-18 Month 95-101 (N= 87; 56)","categories":[{"measurements":[{"groupId":"OG000","value":"246.5","lowerLimit":"197.6","upperLimit":"307.5"},{"groupId":"OG001","value":"4.6","lowerLimit":"3.7","upperLimit":"5.6"}]}]}]},{"type":"SECONDARY","title":"Anti-HPV-16 and Anti-HPV-18 Pseudovirion-based Neutralization Assay (PBNA) Titers in the Immunogenicity Subset","description":"Data are expressed as Geometric Mean Titers (GMTs). The titer is the serum dilution giving a 50 percent reduction of the signal compared to a control without serum","populationDescription":"The analyses were performed on a subset of the ATP cohort for immunogenicity, which included evaluable subjects for whom immunogenicity data were available.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titer","timeFrame":"At Months 77-101","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"8"}]}],"classes":[{"title":"Anti-HPV-16 Month 77-82 (N= 15; 4)","categories":[{"measurements":[{"groupId":"OG000","value":"1616.1","lowerLimit":"592.7","upperLimit":"4407.0"},{"groupId":"OG001","value":"20.0","lowerLimit":"20.0","upperLimit":"20.0"}]}]},{"title":"Anti-HPV-16 Month 83-88 (N= 30; 8)","categories":[{"measurements":[{"groupId":"OG000","value":"1990.7","lowerLimit":"1228.5","upperLimit":"3225.8"},{"groupId":"OG001","value":"20.0","lowerLimit":"20.0","upperLimit":"20.0"}]}]},{"title":"Anti-HPV-16 Month 89-94 (N= 18; 6)","categories":[{"measurements":[{"groupId":"OG000","value":"1385.0","lowerLimit":"740.6","upperLimit":"2590.0"},{"groupId":"OG001","value":"20.0","lowerLimit":"20.0","upperLimit":"20.0"}]}]},{"title":"Anti-HPV-16 Month 95-101 (N= 27; 6)","categories":[{"measurements":[{"groupId":"OG000","value":"1611.6","lowerLimit":"934.1","upperLimit":"2780.3"},{"groupId":"OG001","value":"20.0","lowerLimit":"20.0","upperLimit":"20.0"}]}]},{"title":"Anti-HPV-18 Month 77-82 (N= 15; 4)","categories":[{"measurements":[{"groupId":"OG000","value":"845.4","lowerLimit":"361.6","upperLimit":"1976.7"},{"groupId":"OG001","value":"20.0","lowerLimit":"20.0","upperLimit":"20.0"}]}]},{"title":"Anti-HPV-18 Month 83-88 (N= 30; 8)","categories":[{"measurements":[{"groupId":"OG000","value":"751.6","lowerLimit":"466.3","upperLimit":"1211.5"},{"groupId":"OG001","value":"20.0","lowerLimit":"20.0","upperLimit":"20.0"}]}]},{"title":"Anti-HPV-18 Month 89-94 (N= 18; 6)","categories":[{"measurements":[{"groupId":"OG000","value":"1185.3","lowerLimit":"656.1","upperLimit":"2141.1"},{"groupId":"OG001","value":"20.0","lowerLimit":"20.0","upperLimit":"20.0"}]}]},{"title":"Anti-HPV-18 Month 95-101 (N= 27; 6)","categories":[{"measurements":[{"groupId":"OG000","value":"578.2","lowerLimit":"352.9","upperLimit":"947.1"},{"groupId":"OG001","value":"20.0","lowerLimit":"20.0","upperLimit":"20.0"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With New Onset Chronic Diseases (NOCD) up to Year 7","description":"NOCDs include for example asthma, type I diabetes, allergies, ...","populationDescription":"The analysis was performed on the Total Cohort, which included all enrolled subjects who came at the first visit and received at least one vaccine dose (Cervarix or placebo)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"subjects","timeFrame":"Up to year 7","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"222"},{"groupId":"OG001","value":"211"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With NOCD up to Year 8","description":"NOCDs included for example asthma, type I diabetes, allergies, ...\n\nNOCDs which were not unblinded at the subject level at the time of the analysis are not presented and will be disclosed as soon as they become available.","populationDescription":"The analysis was performed on the Total Cohort, which included all enrolled subjects who came at the first visit and received at least one vaccine dose (Cervarix or placebo)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"subjects","timeFrame":"Up to year 8","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"223"},{"groupId":"OG001","value":"213"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With New Onset Autoimmune Disease (NOAD) up to Year 7","populationDescription":"The analysis was performed on the Total Cohort, which included all enrolled subjects who came at the first visit and received at least one vaccine dose (Cervarix or placebo)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"subjects","timeFrame":"Up to year 7","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"222"},{"groupId":"OG001","value":"211"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With NOAD up to Year 8","description":"The values of NOADs are not yet corresponding to the values in each group. The cases are still blinded. They will be disclosed as soon as the results will be available.","populationDescription":"The analysis was performed on the Total Cohort, which included all enrolled subjects who came at the first visit and received at least one vaccine dose (Cervarix or placebo)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"subjects","timeFrame":"Up to year 8","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"223"},{"groupId":"OG001","value":"213"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Medically Significant Conditions up to Year 7","description":"Medically significant conditions include adverse events (AEs) prompting emergency room or physician visits that are not related to common diseases or routine visits for physical examination or vaccination, or serious adverse events (SAEs) that are not related to common diseases. Common diseases include upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervico-vaginal yeast infections, menstrual cycle abnormalities and injury.\n\nMedically significant conditions which were not unblinded at the time of the analysis are not presented yet.","populationDescription":"The analysis was performed on the Total Cohort, which included all enrolled subjects who came at the first visit and received at least one vaccine dose (Cervarix or placebo)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"subjects","timeFrame":"Up to year 7","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"222"},{"groupId":"OG001","value":"211"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"13"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Medically Significant Conditions up to Year 8","description":"Medically significant conditions include adverse events (AEs) prompting emergency room or physician visits that are not related to common diseases or routine visits for physical examination or vaccination, or serious adverse events (SAEs) that are not related to common diseases. Common diseases include upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervico-vaginal yeast infections, menstrual cycle abnormalities and injury.\n\nMedically significant conditions which were not unblinded at the time of the analysis are not presented yet.","populationDescription":"The analysis was performed on the Total Cohort, which included all enrolled subjects who came at the first visit and received at least one vaccine dose (Cervarix or placebo)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"subjects","timeFrame":"up to year 8","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"223"},{"groupId":"OG001","value":"213"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"24"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Serious Adverse Events (SAEs) up to Year 7","description":"SAEs assessed include medical occurrences that result in death, is life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject","populationDescription":"The analysis was performed on the Total Cohort, which included all enrolled subjects who came at the first visit and received at least one vaccine dose (Cervarix or placebo)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"subjects","timeFrame":"Up to year 7","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"222"},{"groupId":"OG001","value":"211"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With SAEs up to Year 8","description":"SAEs assessed include medical occurrences that result in death, is life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject","populationDescription":"The analysis was performed on the Total Cohort, which included all enrolled subjects who came at the first visit and received at least one vaccine dose (Cervarix or placebo)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"subjects","timeFrame":"up to year 8","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"223"},{"groupId":"OG001","value":"213"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"7"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Presenting Cervical Infections With Any Oncogenic HPV Type.","description":"Oncogenic HPV types included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had a normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at month 6 in the primary study.","populationDescription":"The According -To-Protocol (ATP) cohort for efficacy included all subjects for whom differential treatment effect on efficacy was likely (i.e. those meeting all eligibility criteria in the primary study (580299/001), the first follow-up (580299/007) and the current study), who complied with the protocol and for whom efficacy data were available.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"Up to year 9","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"155"},{"groupId":"OG001","value":"136"}]}],"classes":[{"title":"Including HPV-16 or 18 (N=155;135)","categories":[{"measurements":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"49"}]}]},{"title":"Without HPV-16 or 18 (N=155;136)","categories":[{"measurements":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"45"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Presenting Cervical Infections With Individual Oncogenic Non-vaccine HPV Type","description":"Oncogenic types included HPV-31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies and were DNA negative for the corresponding HPV type at month 6 in the primary study.","populationDescription":"The According -To-Protocol (ATP) cohort for efficacy included all subjects for whom differential treatment effect on efficacy was likely (i.e. those meeting all eligibility criteria in the primary study (580299/001), the first follow-up (580299/007) and the current study), who complied with the protocol and for whom efficacy data were available.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"Up to year 9","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"203"},{"groupId":"OG001","value":"182"}]}],"classes":[{"title":"HPV-31 (N=197;170)","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"}]}]},{"title":"HPV-33 (N=197;177)","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"}]}]},{"title":"HPV-35 (N=197;179)","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"9"}]}]},{"title":"HPV-39 (N=191;163)","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"}]}]},{"title":"HPV-45 (N=203;176)","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"}]}]},{"title":"HPV-51 (N=167;154)","categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"15"}]}]},{"title":"HPV-52 (N=172;153)","categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"10"}]}]},{"title":"HPV-56 (N=182;170)","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"}]}]},{"title":"HPV-58 (N=191;175)","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"3"}]}]},{"title":"HPV-59 (N=195;182)","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}]},{"title":"HPV-66 (N=176;165)","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"10"}]}]},{"title":"HPV-68 (N=188;166)","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"9"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Persistent Infection (6-month Definition) With HPV-16 and/or HPV-18","description":"Persistent cervical HPV infection (6-month definition) was defined as detection of the same HPV type in cervical specimens at 2 consecutive evaluations over a minimum of 5 months.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had a normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at month 6 in the primary study","populationDescription":"The According -To-Protocol (ATP) cohort for efficacy included all subjects for whom differential treatment effect on efficacy was likely (i.e. those meeting all eligibility criteria in the primary study (580299/001), the first follow-up (580299/007) and the current study, who complied with the protocol and for whom efficacy data were available.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"Up to year 9","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"179"},{"groupId":"OG001","value":"152"}]}],"classes":[{"title":"HPV-16/18 (N=179;144)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"}]}]},{"title":"HPV-16 (N=179;149)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"}]}]},{"title":"HPV-18 (N=179;152)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Persistent Infection (6-month Definition) With Any Oncogenic HPV Type","description":"Oncogenic HPV types included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nPersistent cervical HPV infection (6-month definition) was defined as detection of the same HPV type in cervical specimens at 2 consecutive evaluations over a minimum of 5 months.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had a normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at month 6 in the primary study.","populationDescription":"The According-To-Protocol (ATP) cohort for efficacy included all subjects for whom differential treatment effect on efficacy was likely (i.e. those meeting all eligibility criteria in the primary study (580299/001), the first follow-up (580299/007) and the current study), who complied with the protocol and for whom efficacy data were available.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"Up to year 9","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"144"}]}],"classes":[{"title":"Including HPV-16 or 18 (N=163;143)","categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"25"}]}]},{"title":"Without HPV-16 or 18 (N=163;144)","categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"24"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Persistent Infection (6-month Definition) With Individual Oncogenic Non-vaccine HPV Types","description":"Oncogenic HPV types included HPV-31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nPersistent cervical HPV infection (6-month definition) was defined as detection of the same HPV type in cervical specimens at 2 consecutive evaluations over a minimum of 5 months.\n\nSubjects with an event did not report the same event during the earlier studies. Subjects with an event were DNA negative for the corresponding HPV type at Month 6 in the primary study.","populationDescription":"The According-To-Protocol (ATP) cohort for efficacy included all subjects for whom differential treatment effect on efficacy was likely (i.e. those meeting all eligibility criteria in the primary study (580299/001), the first follow-up (580299/007) and the current study), who complied with the protocol and for whom efficacy data were available.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"Up to year 9","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"205"},{"groupId":"OG001","value":"186"}]}],"classes":[{"title":"HPV-31 (N=203;182)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"}]}]},{"title":"HPV-33 (N=201;184)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-35 (N=202;182)","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"}]}]},{"title":"HPV-39 (N=201;176)","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"}]}]},{"title":"HPV-45 (N=205;186)","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-51 (N=193;176)","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"}]}]},{"title":"HPV-52 (N=187;167)","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"7"}]}]},{"title":"HPV-56 (N=198;184)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"}]}]},{"title":"HPV-58 (N=197;183)","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"}]}]},{"title":"HPV-59 (N=204;186)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-66 (N=192;172)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"5"}]}]},{"title":"HPV-68 (N=201;182)","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Persistent Infection (12-month Definition) With HPV-16 and/or HPV-18","description":"Persistent cervical HPV infection (12-month definition) was defined as detection of the same HPV type in cervical specimens at all consecutive evaluations over a minimum of 10 months.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had a normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at month 6 in the primary study","populationDescription":"The According-To-Protocol (ATP) cohort for efficacy included all subjects for whom differential treatment effect on efficacy was likely (i.e. those meeting all eligibility criteria in the primary study (580299/001), the first follow-up (580299/007) and the current study), who complied with the protocol and for whom efficacy data were available.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"Up to year 9","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"179"},{"groupId":"OG001","value":"157"}]}],"classes":[{"title":"HPV-16/18 (N=179;153)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-16 (N=179;155)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-18 (N=179;157)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Persistent Infection (12-month Definition) With Any Oncogenic HPV Types","description":"Oncogenic HPV types included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nPersistent cervical HPV infection (12-month definition) was defined as detection of the same HPV type in cervical specimens at all consecutive evaluations over a minimum of 10 months.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had a normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at month 6 in the primary study.","populationDescription":"The According-To-Protocol (ATP) cohort for efficacy included all subjects for whom differential treatment effect on efficacy was likely (i.e. those meeting all eligibility criteria in the primary study (580299/001), the first follow-up (580299/007) and the current study), who complied with the protocol and for whom efficacy data were available.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"Up to year 9","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"164"},{"groupId":"OG001","value":"144"}]}],"classes":[{"title":"Including HPV-16 or 18 (N=164;143)","categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"10"}]}]},{"title":"Without HPV-16 or 18 (N=164;144)","categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"8"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Persistent Infection (12-month Definition) With Individual Oncogenic Non-vaccine HPV Types","description":"Individual oncogenic non-vaccine HPV types include HPV-31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nPersistent cervical HPV infection (12-month definition) was defined as detection of the same HPV type in cervical specimens at all consecutive evaluations over a minimum of 10 months.\n\nSubjects with an event did not report the same event in the earlier studies and were DNA negative for the corresponding HPV type at month 6 in the primary study","populationDescription":"The According-To-Protocol (ATP) cohort for efficacy included all subjects for whom differential treatment effect on efficacy was likely (i.e. those meeting all eligibility criteria in the primary study (580299/001), the first follow-up (580299/007) and the current study), who complied with the protocol and for whom efficacy data were available.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"Up to year 9","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"206"},{"groupId":"OG001","value":"188"}]}],"classes":[{"title":"HPV-31 (N=204,183)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"}]}]},{"title":"HPV-33 (N=204;186)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-35 (N=202;187)","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}]},{"title":"HPV-39 (N=202;181)","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-45 (N=206;188)","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-51 (N=200;184)","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}]},{"title":"HPV-52 (N=193;174)","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}]},{"title":"HPV-56 (N=202;187)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-58 (N=201;185)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-59 (N=205;188)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-66 (N=196;179)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-68 (N=202;185)","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Histopathologically-confirmed CIN1+ Associated With HPV-16 or HPV-18 Detected Within the Lesional Component of the Cervical Tissue Specimen","description":"Cervical Intraepithelial Neoplasia (CIN1)+ was defined as CIN grades 1,2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at Month 6 in the primary study.","populationDescription":"The analyses was performed on the Total Cohort, which included all enrolled subjects who came at the first visit and received at least one vaccine dose (Cervarix or Placebo)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"Up to year 9","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"200"},{"groupId":"OG001","value":"187"}]}],"classes":[{"title":"HPV-16/18 (N=200;183)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-16 (N=200;184)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-18 (N=200;187)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Histopathologically Confirmed CIN1+ Associated With Oncogenic HPV Types Detected Within the Lesional Component of the Cervical Tissue Specimen","description":"CIN1+ was defined as CIN grades 1,2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer.\n\nOncogenic HPV types assessed included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at Month 6 in the primary study.","populationDescription":"The analyses was performed on the Total Cohort, which included all enrolled subjects who came at the first visit and received at least one vaccine dose (Cervarix or Placebo)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"Up to year 9","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"200"},{"groupId":"OG001","value":"188"}]}],"classes":[{"title":"Including HPV-16 or 18 (N=200;188)","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"}]}]},{"title":"Without HPV-16 or 18 (N=200;188)","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Histopathologically Confirmed CIN1+ Associated With Individual Oncogenic Non-Vaccine HPV Types Detected Within the Lesional Component of the Cervical Tissue Specimen","description":"CIN1+ was defined as CIN grades 1,2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer.\n\nOncogenic HPV types assessed included HPV-31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies and were DNA negative for the corresponding HPV type at Month 6 in the primary study.","populationDescription":"The analyses was performed on the Total Cohort, which included all enrolled subjects who came at the first visit and received at least one vaccine dose (Cervarix or Placebo)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"Up to year 9","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"224"},{"groupId":"OG001","value":"211"}]}],"classes":[{"title":"HPV-31 (N=223;209)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-33 (N=222;209)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-35 (N=221;208)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-39 (N=224;211)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-45 (N=223;210)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-51 (N=217;208)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-52 (N=220;206)","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}]},{"title":"HPV-56 (N=221;211)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-58 (N=223;208)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]},{"title":"HPV-59 (N=222;210)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-66 (N=220;205)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-68 (N=223;210)","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Histopathologically-confirmed CIN2+ Associated With HPV-16 or HPV-18 Detected Within the Lesional Component of the Cervical Tissue Specimen","description":"CIN2+ was defined as CIN grades 2 and 3, AIS and invasive cervical cancer.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at Month 6 in the primary study.","populationDescription":"The analyses was performed on the Total Cohort, which included all enrolled subjects who came at the first visit and received at least one vaccine dose (Cervarix or Placebo)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"Up to year 9","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"200"},{"groupId":"OG001","value":"187"}]}],"classes":[{"title":"HPV-16/18 (N=200;185)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-16 (N=200;186)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-18 (N=200;187)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Histopathologically Confirmed CIN2+ Associated With Oncogenic HPV Types Detected Within the Lesional Component of the Cervical Tissue Specimen","description":"CIN2+ was defined as CIN grades 2 and 3, AIS and invasive cervical cancer.\n\nOncogenic HPV types assessed included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at Month 6 in the primary study.","populationDescription":"The analyses was performed on the Total Cohort, which included all enrolled subjects who came at the first visit and received at least one vaccine dose (Cervarix or Placebo)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"Up to year 9","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"200"},{"groupId":"OG001","value":"188"}]}],"classes":[{"title":"Including HPV-16 or 18 (N=200;188)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]},{"title":"Without HPV-16 or 18 (N=200;188)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Histopathologically Confirmed CIN2+ Associated With Individual Oncogenic Non-Vaccine HPV Types Detected Within the Lesional Component of the Cervical Tissue Specimen","description":"CIN2+ was defined as CIN grades 2 and 3, AIS and invasive cervical cancer.\n\nOncogenic HPV types assessed included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies and were DNA negative for the corresponding HPV type at Month 6 in the primary study.","populationDescription":"The analyses was performed on the Total Cohort, which included all enrolled subjects who came at the first visit and received at least one vaccine dose (Cervarix or Placebo)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"Up to year 9","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"224"},{"groupId":"OG001","value":"211"}]}],"classes":[{"title":"HPV-31 (N=223;210)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-33 (N=222;210)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-35 (N=222;208)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-39 (N=224;211)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-45 (N=223;210)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-51 (N=219;209)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-52 (N=220;208)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-56 (N=221;211)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-58 (N=223;209)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]},{"title":"HPV-59 (N=222;210)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-66 (N=221;207)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-68 (N=223;210)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Abnormal Cytology Greater Than or Equal to Atypical Squamous Cells of Undertermined Significance (ASC-US) Associated With an HPV 16 and/or HPV-18 Cervical Infection","description":"Abnormal cytology included atypical squamus cells of undetermined significance (ASC-US), low-grade squamous intraepithelial lesion (LSIL), high-grade squamous intraepithelial lesion (HSIL), atypical glandular cells (AGC), atypical squamus cells and cannot exclude HSIL (ASC-H).\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at Month 6 in the primary study","populationDescription":"The analyses was performed on the Total Cohort, which included all enrolled subjects who came at the first visit and received at least one vaccine dose (Cervarix or Placebo)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"Up to year 9","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"200"},{"groupId":"OG001","value":"178"}]}],"classes":[{"title":"HPV-16/18 (N=199;165)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"}]}]},{"title":"HPV-16 (N=199;171)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-18 (N=200;178)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Abnormal Cytology Greater Than or Equal to Atypical Squamous Cells of Undertermined Significance (ASC-US) Associated With Oncogenic HPV Types Cervical Infection","description":"Abnormal cytology included ASC-US, LSIL, HSIL, AGC, and ASC-H.\n\nOncogenic HPV types assessed included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at Month 6 in the primary study.","populationDescription":"The analyses was performed on the Total Cohort, which included all enrolled subjects who came at the first visit and received at least one vaccine dose (Cervarix or Placebo)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"Up to year 9","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"185"}]}],"classes":[{"title":"Including HPV-16 or 18 (N=197;184)","categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"25"}]}]},{"title":"Without HPV-16 or 18 (N=197;185)","categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"25"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Abnormal Cytology Greater Than or Equal to Atypical Squamous Cells of Undertermined Significance (ASC-US) Associated With Individual Oncogenic Non-vaccine HPV Types Cervical Infection","description":"Abnormal cytology included ASC-US, LSIL, HSIL, AGC and ASC-H.\n\nOncogenic HPV types assessed included HPV-31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies and were DNA negative for the corresponding HPV type at month 6 in the primary study","populationDescription":"The analyses was performed on the Total Cohort, which included all enrolled subjects who came at the first visit and received at least one vaccine dose (Cervarix or Placebo)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"Up to year 9","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"222"},{"groupId":"OG001","value":"208"}]}],"classes":[{"title":"HPV-31 (N=219;202)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"5"}]}]},{"title":"HPV-33 (N=220;204)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]},{"title":"HPV-35 (N=219;204)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"}]}]},{"title":"HPV-39 (N=219;198)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-45 (N=222;206)","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-51 (N=203;196)","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"7"}]}]},{"title":"HPV-52 (N=207;184)","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"5"}]}]},{"title":"HPV-56 (N=208;204)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-58 (N=215;201)","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"}]}]},{"title":"HPV-59 (N=218;208)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]},{"title":"HPV-66 (N=214;195)","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}]},{"title":"HPV-68 (N=219;202)","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Abnormal Cytology Greater Than or Equal to Low-grade Squamous Intraepithelial Lesion (LSIL) Associated With an HPV 16 and/or HPV-18 Cervical Infection","description":"Abnormal cytology included ASC-US, LSIL, HSIL, AGC and ASC-H.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at Month 6 in the primary study.","populationDescription":"The analyses was performed on the Total Cohort, which included all enrolled subjects who came at the first visit and received at least one vaccine dose (Cervarix or Placebo)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"Up to year 9","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"200"},{"groupId":"OG001","value":"184"}]}],"classes":[{"title":"HPV-16/18 (N=199;174)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]},{"title":"HPV-16 (N=199;177)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-18 (N=200;184)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Abnormal Cytology Greater Than or Equal to Low-grade Squamous Intraepithelial Lesion (LSIL) Associated With Oncogenic HPV Types Cervical Infection","description":"Abnormal cytology included ASC-US, LSIL, HSIL, AGC, and ASC-H.\n\nOncogenic HPV types assessed included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at Month 6 in the primary study.","populationDescription":"The analyses was performed on the Total Cohort, which included all enrolled subjects who came at the first visit and received at least one vaccine dose (Cervarix or Placebo)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"Up to year 9","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"187"}]}],"classes":[{"title":"Including HPV-16 or 18 (N=198;187)","categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"19"}]}]},{"title":"Without HPV-16 or 18 (N=198;187)","categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"19"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Abnormal Cytology Greater Than or Equal to Low-grade Squamous Intraepithelial Lesion (LSIL) Associated With Individual Oncogenic Non-vaccine HPV Types Cervical Infection","description":"Abnormal cytology included ASC-US, LSIL, HSIL, AGC and ASC-H.\n\nOncogenic HPV types assessed included HPV-31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies and were DNA negative for the corresponding HPV type at month 6 in the primary study.","populationDescription":"The analyses was performed on the Total Cohort, which included all enrolled subjects who came at the first visit and received at least one vaccine dose (Cervarix or Placebo)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"Up to year 9","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"222"},{"groupId":"OG001","value":"209"}]}],"classes":[{"title":"HPV-031 (N=220;204)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"5"}]}]},{"title":"HPV-33 (N=221;207)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]},{"title":"HPV-35 (N=219;206)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-39 (N=221;201)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-45 (N=222;207)","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-51 (N=212;199)","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"5"}]}]},{"title":"HPV-52 (N=212;192)","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"}]}]},{"title":"HPV-56 (N=212;204)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-58 (N=218;205)","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"}]}]},{"title":"HPV-59 (N=221;209)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-66 (N=217;196)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]},{"title":"HPV-68 (N=221;206)","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}]}]},{"type":"SECONDARY","title":"Anti-HPV-16 and Anti-HPV-18 Enzyme-linked Immunosorbent Assay (ELISA) Titers in the Immunogenicity Cohort","description":"Titers are given as Geometric Mean Titers (GMTs) expressed as Enzyme-linked immunosorbent assay (ELISA) Units per milliliter (EL.U/mL).\n\nThe cut-off-vales assessed were \\>= 8 or 7 EL. U/mL for anti-HPV-16 and 18, respectively.","populationDescription":"The analyses were performed on the ATP cohort for immunogenicity, which included evaluable subjects for whom immunogenicity data were available.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"EL. U/mL","timeFrame":"At Month 77 until year 9 (Month 113)","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"111"},{"groupId":"OG001","value":"65"}]}],"classes":[{"title":"Anti-HPV-16 Month 77-82 (N=69;52)","categories":[{"measurements":[{"groupId":"OG000","value":"374.9","lowerLimit":"291.8","upperLimit":"481.8"},{"groupId":"OG001","value":"5.2","lowerLimit":"4.3","upperLimit":"6.2"}]}]},{"title":"Anti-HPV-16 Month 83-88 (N=111;65)","categories":[{"measurements":[{"groupId":"OG000","value":"383.4","lowerLimit":"312.9","upperLimit":"469.9"},{"groupId":"OG001","value":"5.2","lowerLimit":"4.4","upperLimit":"6.1"}]}]},{"title":"Anti-HPV-16 Month 89-94 (N=94;65)","categories":[{"measurements":[{"groupId":"OG000","value":"346.3","lowerLimit":"270.3","upperLimit":"443.6"},{"groupId":"OG001","value":"5.4","lowerLimit":"4.4","upperLimit":"6.7"}]}]},{"title":"Anti-HPV-16 Month 95-100 (N=87;53)","categories":[{"measurements":[{"groupId":"OG000","value":"435.1","lowerLimit":"347.5","upperLimit":"544.9"},{"groupId":"OG001","value":"5.4","lowerLimit":"4.4","upperLimit":"6.7"}]}]},{"title":"Anti-HPV-16 Month 101-106 (N=87;63)","categories":[{"measurements":[{"groupId":"OG000","value":"322.8","lowerLimit":"249.4","upperLimit":"417.6"},{"groupId":"OG001","value":"5.2","lowerLimit":"4.3","upperLimit":"6.3"}]}]},{"title":"Anti-HPV-16 Month 107-113 (N=92;60)","categories":[{"measurements":[{"groupId":"OG000","value":"418.3","lowerLimit":"344.0","upperLimit":"508.6"},{"groupId":"OG001","value":"6.1","lowerLimit":"4.9","upperLimit":"7.8"}]}]},{"title":"Anti-HPV-18 Month 77-82 (N=69;52)","categories":[{"measurements":[{"groupId":"OG000","value":"252.8","lowerLimit":"196.9","upperLimit":"324.7"},{"groupId":"OG001","value":"4.2","lowerLimit":"3.6","upperLimit":"4.9"}]}]},{"title":"Anti-HPV-18 Month 83-88 (N=111;65)","categories":[{"measurements":[{"groupId":"OG000","value":"251.0","lowerLimit":"208.7","upperLimit":"301.8"},{"groupId":"OG001","value":"5.0","lowerLimit":"4.1","upperLimit":"6.1"}]}]},{"title":"Anti-HPV-18 Month 89-94 (N=94;65)","categories":[{"measurements":[{"groupId":"OG000","value":"234.6","lowerLimit":"188.8","upperLimit":"291.5"},{"groupId":"OG001","value":"4.4","lowerLimit":"3.7","upperLimit":"5.2"}]}]},{"title":"Anti-HPV-18 Month 95-100 (N=87;53)","categories":[{"measurements":[{"groupId":"OG000","value":"246.5","lowerLimit":"197.6","upperLimit":"307.5"},{"groupId":"OG001","value":"4.6","lowerLimit":"3.7","upperLimit":"5.8"}]}]},{"title":"Anto-HPV-18 Month 101-106 (N=87;63)","categories":[{"measurements":[{"groupId":"OG000","value":"225.0","lowerLimit":"177.1","upperLimit":"285.8"},{"groupId":"OG001","value":"4.1","lowerLimit":"3.6","upperLimit":"4.6"}]}]},{"title":"Anti-HPV-18 Month 107-113 (N=92;60)","categories":[{"measurements":[{"groupId":"OG000","value":"242.6","lowerLimit":"199.3","upperLimit":"295.2"},{"groupId":"OG001","value":"4.8","lowerLimit":"3.9","upperLimit":"6.0"}]}]}]},{"type":"SECONDARY","title":"Anti-HPV-16 and Anti-HPV-18 Pseudovirion-based Neutralization Assay (PBNA) Titers in the Immunogenicity Subset","description":"Data are expressed as Geometric Mean Titers (GMTs). The titer is the serum dilution giving a 50 percent reduction of the signal compared to a control without serum","populationDescription":"The analyses were performed on the ATP cohort for immunogenicity, which included evaluable subjects for whom immunogenicity data were available.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"At Month 77 until year 9 (Month 113)","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"8"}]}],"classes":[{"title":"Anti-HPV-16 Month 77-82 (N=15;4)","categories":[{"measurements":[{"groupId":"OG000","value":"1616.1","lowerLimit":"592.7","upperLimit":"4407.0"},{"groupId":"OG001","value":"20.0","lowerLimit":"20.0","upperLimit":"20.0"}]}]},{"title":"Anti-HPV-16 Month 83-88 (N=30;8)","categories":[{"measurements":[{"groupId":"OG000","value":"1990.7","lowerLimit":"1228.5","upperLimit":"3225.8"},{"groupId":"OG001","value":"20.0","lowerLimit":"20.0","upperLimit":"20.0"}]}]},{"title":"Anti-HPV-16 Month 89-94 (N=18;6)","categories":[{"measurements":[{"groupId":"OG000","value":"1385.0","lowerLimit":"740.6","upperLimit":"2590.0"},{"groupId":"OG001","value":"20.0","lowerLimit":"20.0","upperLimit":"20.0"}]}]},{"title":"Anti-HPV-16 Month 95-101 (N=27;6)","categories":[{"measurements":[{"groupId":"OG000","value":"1611.6","lowerLimit":"934.1","upperLimit":"2780.3"},{"groupId":"OG001","value":"20.0","lowerLimit":"20.0","upperLimit":"20.0"}]}]},{"title":"Anti-HPV-16 Month 101-106 (N=16;7)","categories":[{"measurements":[{"groupId":"OG000","value":"1380.7","lowerLimit":"667.5","upperLimit":"2855.8"},{"groupId":"OG001","value":"20.0","lowerLimit":"20.0","upperLimit":"20.0"}]}]},{"title":"Anti-HPV-16 Month 107-113 (N=30;5)","categories":[{"measurements":[{"groupId":"OG000","value":"1549.8","lowerLimit":"1027.9","upperLimit":"2336.8"},{"groupId":"OG001","value":"20.0","lowerLimit":"20.0","upperLimit":"20.0"}]}]},{"title":"Anti-HPV-18 Month 77-82 (N=15;4)","categories":[{"measurements":[{"groupId":"OG000","value":"845.4","lowerLimit":"361.6","upperLimit":"1976.7"},{"groupId":"OG001","value":"20.0","lowerLimit":"20.0","upperLimit":"20.0"}]}]},{"title":"Anti-HPV-18 Month 83-88 (N=30;8)","categories":[{"measurements":[{"groupId":"OG000","value":"751.6","lowerLimit":"466.3","upperLimit":"1211.5"},{"groupId":"OG001","value":"20.0","lowerLimit":"20.0","upperLimit":"20.0"}]}]},{"title":"Anti-HPV-18 Month 89-94 (N=18;6)","categories":[{"measurements":[{"groupId":"OG000","value":"1185.3","lowerLimit":"656.1","upperLimit":"2141.1"},{"groupId":"OG001","value":"20.0","lowerLimit":"20.0","upperLimit":"20.0"}]}]},{"title":"Anti-HPV-18 Month 95-101 (N=27;6)","categories":[{"measurements":[{"groupId":"OG000","value":"578.2","lowerLimit":"352.9","upperLimit":"947.1"},{"groupId":"OG001","value":"20.0","lowerLimit":"20.0","upperLimit":"20.0"}]}]},{"title":"Anti-HPV-18 Month 101-106 (N=16;7)","categories":[{"measurements":[{"groupId":"OG000","value":"860.1","lowerLimit":"441.0","upperLimit":"1677.3"},{"groupId":"OG001","value":"20.0","lowerLimit":"20.0","upperLimit":"20.0"}]}]},{"title":"Anti-HPV-18 Month 107-113 (N=30;5)","categories":[{"measurements":[{"groupId":"OG000","value":"552.0","lowerLimit":"358.5","upperLimit":"850.1"},{"groupId":"OG001","value":"20.0","lowerLimit":"20.0","upperLimit":"20.0"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With New Onset Chronic Diseases (NOCD) up to Year 9","description":"NOCDs include for example asthma, type I diabetes, allergies, ...","populationDescription":"The analyses was performed on the Total Cohort, which included all enrolled subjects who came at the first visit and received at least one vaccine dose (Cervarix or Placebo).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"Up to year 9","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"224"},{"groupId":"OG001","value":"213"}]}],"classes":[{"title":"Number of Subjects With NOCD up to Year 9","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"3"}]}]},{"title":"Hypothyroidism","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}]},{"title":"Drug hypersensitivity","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Rhinitis allergic","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Type 2 diabetes mellitus","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Rheumatoid arthritis","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Dermatitis allergic","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Skin reaction","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Vitiligo","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Hypertension","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With New Onset Autoimmune Disease (NOAD) up to Year 9.","populationDescription":"The analyses was performed on the Total Cohort, which included all enrolled subjects who came at the first visit and received at least one vaccine dose (Cervarix or Placebo)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"Up to year 9","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"224"},{"groupId":"OG001","value":"213"}]}],"classes":[{"title":"Number of Subjects With NOAD up to Year 9","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"}]}]},{"title":"Hypothyroidism","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}]},{"title":"Rheumatoid arthritis","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Vitiligo","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Medically Signifant Conditions up to Year 9","description":"Medically significant conditions include adverse events (AEs) prompting emergency room or physician visits that are not related to common diseases or routine visits for physical examination or vaccination, or serious adverse events (SAEs) that are not related to common diseases. Common diseases include upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervico-vaginal yeast infections, menstrual cycle abnormalities and injury.","populationDescription":"The analyses was performed on the Total Cohort, which included all enrolled subjects who came at the first visit and received at least one vaccine dose (Cervarix or Placebo)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"Up to year 9","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"224"},{"groupId":"OG001","value":"213"}]}],"classes":[{"title":"Medically Signifant Conditions up to Year 9","categories":[{"measurements":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"38"}]}]},{"title":"Gastritis","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"}]}]},{"title":"Hypertension","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"}]}]},{"title":"Abortion spontaneous incomplete","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"1"}]}]},{"title":"Depression","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"1"}]}]},{"title":"Nephrolithiasis","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"}]}]},{"title":"Abortion missed","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}]},{"title":"Hypothyroidism","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}]},{"title":"Panic disorder","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}]},{"title":"Bursitis","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]},{"title":"Ovarian cyst","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]},{"title":"Ovarian disorder","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]},{"title":"Anaemia","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]},{"title":"Gynaecological chlamydia infection","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]},{"title":"Pneumonia","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Pyelonephritis","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Blood pressure increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Bipolar disorder","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Genital herpes","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"}]}]},{"title":"Haemorrhoids","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Peptic ulcer","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Vomiting","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Chest pain","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Cholelithiasis","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Breast infection","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Dengue fever","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Erysipelas","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Gingival abscess","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Pelvic inflammatory disease","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Staphylococcal infection","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Toxoplasmosis","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Abnormal loss of weight","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Metabolic syndrome","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Cervical spinal stenosis","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Synovial cyst","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Tendonitis","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Benign breast neoplasm","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Benign hydatidiform mole","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Ovarian cancer","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Headache","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Blighted ovum","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Intra-uterine death","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Oligohydramnios","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Pre-eclampsia","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Rhinitis allergic","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Dermatitis allergic","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Sexual abuse","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Haematoma","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Serious Adverse Events (SAEs) up to Year 9.","description":"SAEs assessed include medical occurrences that result in death, is life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject","populationDescription":"The analyses was performed on the Total Cohort, which included all enrolled subjects who came at the first visit and received at least one vaccine dose (Cervarix or Placebo)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"up to year 9","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"224"},{"groupId":"OG001","value":"213"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"11"}]}]}]},{"type":"PRIMARY","title":"Number of Subjects Presenting Cervical Infections With Human Papillomavirus (HPV) -16 and/or HPV-18","description":"Cervical HPV infection was defined as the first detection of an HPV type in a subject previously negative for that HPV type","populationDescription":"The According-To-Protocol (ATP) cohort for efficacy included all subjects for whom differential treatment effect on efficacy was likely (i.e. those meeting all eligibility criteria in the primary study (580299/001), the first follow-up (580299/007) and the current study), who complied with the protocol and for whom efficacy data were available.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"Up to year 9","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"179"},{"groupId":"OG001","value":"140"}]}],"classes":[{"title":"HPV-16 (N=179;133)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"9"}]}]},{"title":"HPV-18 (N=177;140)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"6"}]}]},{"title":"HPV-16/18 (N=177;122)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"9"}]}]}]},{"type":"PRIMARY","title":"Number of Subjects Presenting Cervical Infections With Human Papillomavirus (HPV) -16 and /or HPV-18","description":"Cervical HPV infection was defined as the first detection of an HPV type in a subject previously negative for that HPV type.","populationDescription":"The According -To-Protocol (ATP) cohort for efficacy included all subjects for whom differential treatment effect on efficacy was likely (i.e. those meeting all eligibility criteria in the primary study (580299/001), the first follow-up (580299/007) and the current study), who complied with the protocol and for whom efficacy data were available.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"Up to year 7","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"133"}]}],"classes":[{"title":"HPV-16 (N=171;128)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]},{"title":"HPV-18 (N=169;133)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-16/18 (N=169;117)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Presenting Cervical Infections With Any Oncogenic HPV Type.","description":"Oncogenic HPV types included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had a normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at month 6 in the primary study.","populationDescription":"The According -To-Protocol (ATP) cohort for efficacy included all subjects for whom differential treatment effect on efficacy was likely (i.e. those meeting all eligibility criteria in the primary study (580299/001), the first follow-up (580299/007) and the current study), who complied with the protocol and for whom efficacy data were available.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"Up to year 7","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"148"},{"groupId":"OG001","value":"126"}]}],"classes":[{"title":"Including HPV-16 or 18 (N=148;122)","categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"16"}]}]},{"title":"Without HPV-16 or 18 (N=148;126)","categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"14"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Presenting Cervical Infections With Individual Oncogenic Non-vaccine HPV Type.","description":"Oncogenic types included HPV-31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies and were DNA negative for the corresponding HPV type at month 6 in the primary study.","populationDescription":"The According -To-Protocol (ATP) cohort for efficacy included all subjects for whom differential treatment effect on efficacy was likely (i.e. those meeting all eligibility criteria in the primary study (580299/001), the first follow-up (580299/007) and the current study), who complied with the protocol and for whom efficacy data were available.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"Up to year 7","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"193"},{"groupId":"OG001","value":"174"}]}],"classes":[{"title":"HPV-31 (N=187;162)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-33 (N=187;168)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-35 (N=187;170)","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}]},{"title":"HPV-39 (N=181;156)","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-45 (N=193;167)","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"}]}]},{"title":"HPV-51 (N=158;146)","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"}]}]},{"title":"HPV-52 (N=162;147)","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"3"}]}]},{"title":"HPV-56 (N=174;162)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-58 (N=182;166)","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-59 (N=186;174)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-66 (N=169;157)","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}]},{"title":"HPV-68 (N=179;159)","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Persistent Infection (6-month Definition) With HPV-16 and/or HPV-18","description":"Persistent cervical HPV infection (6-month definition) was defined as detection of the same HPV type in cervical specimens at 2 consecutive evaluations over a minimum of 5 months.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had a normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at month 6 in the primary study","populationDescription":"The According -To-Protocol (ATP) cohort for efficacy included all subjects for whom differential treatment effect on efficacy was likely (i.e. those meeting all eligibility criteria in the primary study (580299/001), the first follow-up (580299/007) and the current study), who complied with the protocol and for whom efficacy data were available.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"Up to year 7","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"145"}]}],"classes":[{"title":"HPV-16/18 (N=171;139)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-16 (N=171;144)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-18 (N=171;145)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Persistent Infection (6-month Definition) With Any Oncogenic HPV Type","description":"Oncogenic HPV types included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nPersistent cervical HPV infection (6-month definition) was defined as detection of the same HPV type in cervical specimens at 2 consecutive evaluations over a minimum of 5 months.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had a normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at month 6 in the primary study.","populationDescription":"The According-To-Protocol (ATP) cohort for efficacy included all subjects for whom differential treatment effect on efficacy was likely (i.e. those meeting all eligibility criteria in the primary study (580299/001), the first follow-up (580299/007) and the current study), who complied with the protocol and for whom efficacy data were available.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"Up to year 7","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"138"}]}],"classes":[{"title":"Including HPV-16 or 18 (N=157;137)","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"4"}]}]},{"title":"Without HPV-16 or 18 (N=157;138)","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"4"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Persistent Infection (6-month Definition) With Individual Oncogenic Non-vaccine HPV Types","description":"Oncogenic HPV types included HPV-31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nPersistent cervical HPV infection (6-month definition) was defined as detection of the same HPV type in cervical specimens at 2 consecutive evaluations over a minimum of 5 months.\n\nSubjects with an event did not report the same event during the earlier studies. Subjects with an event were DNA negative for the corresponding HPV type at Month 6 in the primary study.","populationDescription":"The According-To-Protocol (ATP) cohort for efficacy included all subjects for whom differential treatment effect on efficacy was likely (i.e. those meeting all eligibility criteria in the primary study (580299/001), the first follow-up (580299/007) and the current study), who complied with the protocol and for whom efficacy data were available.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"Up to year 7","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"177"}]}],"classes":[{"title":"HPV-31 (N= 193; 173)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]},{"title":"HPV-33 (N=191; 175)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-35 (N=192; 173)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-39 (N=191; 168)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-45 (N=195; 177)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-51 (N=183; 167)","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-52 (N=177; 160)","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-56 (N=189; 175)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-58 (N=188; 174)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-59 (N=195; 177)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-66 (N=183; 164)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-68 (N=191; 174)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Persistent Infection (12-month Definition) With HPV-16 and/or HPV-18","description":"Persistent cervical HPV infection (12-month definition) was defined as detection of the same HPV type in cervical specimens at all consecutive evaluations over a minimum of 10 months.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had a normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at month 6 in the primary study.","populationDescription":"The According-To-Protocol (ATP) cohort for efficacy included all subjects for whom differential treatment effect on efficacy was likely (i.e. those meeting all eligibility criteria in the primary study (580299/001), the first follow-up (580299/007) and the current study), who complied with the protocol and for whom efficacy data were available.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"Up to year 7","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"150"}]}],"classes":[{"title":"HPV-16/18 (N=171;146)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-16 (N=171;148)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-18 (N=171;150)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Persistent Infection (12-month Definition) With Any Oncogenic HPV Type","description":"Oncogenic HPV types included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nPersistent cervical HPV infection (12-month definition) was defined as detection of the same HPV type in cervical specimens at all consecutive evaluations over a minimum of 10 months.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had a normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at month 6 in the primary study.","populationDescription":"The According-To-Protocol (ATP) cohort for efficacy included all subjects for whom differential treatment effect on efficacy was likely (i.e. those meeting all eligibility criteria in the primary study (580299/001), the first follow-up (580299/007) and the current study), who complied with the protocol and for whom efficacy data were available.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"Up to year 7","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"158"},{"groupId":"OG001","value":"138"}]}],"classes":[{"title":"Including HPV-16 or 18 (N=158;138)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Without HPV-16 or 18 (N=158;138)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Persistent Infection (12-month Definition) With Individual Oncogenic Non-vaccine HPV Types","description":"Individual oncogenic non-vaccine HPV types include HPV-31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nPersistent cervical HPV infection (12-month definition) was defined as detection of the same HPV type in cervical specimens at all consecutive evaluations over a minimum of 10 months.\n\nSubjects with an event did not report the same event in the earlier studies and were DNA negative for the corresponding HPV type at month 6 in the primary study.","populationDescription":"The According-To-Protocol (ATP) cohort for efficacy included all subjects for whom differential treatment effect on efficacy was likely (i.e. those meeting all eligibility criteria in the primary study (580299/001), the first follow-up (580299/007) and the current study), who complied with the protocol and for whom efficacy data were available.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"Up to year 7","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"196"},{"groupId":"OG001","value":"179"}]}],"classes":[{"title":"HPV-31 (N=194;174)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-33 (N=194;177)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-35 (N=192;178)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-39 (N=192;173)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-45 (N=196;179)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-51 (N=190;175)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-52 (N=183;166)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-56 (N=193;178)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-58 (N=193;178)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-59 (N=196;179)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-66 (N=187;170)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-68 (N=192;177)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Histopathologically-confirmed CIN1+ Associated With HPV-16 or HPV-18 Detected Within the Lesional Component of the Cervical Tissue Specimen","description":"CIN1+ was defined as CIN grades 1,2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at Month 6 in the primary study.","populationDescription":"The analyses was performed on the Total Cohort, which included all enrolled subjects who came at the first visit and received at least one vaccine dose (Cervarix or Placebo)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"Up to year 7","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"191"},{"groupId":"OG001","value":"178"}]}],"classes":[{"title":"HPV-16/18 (N=191;175)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-16 (N=191;176)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-18 (N=191;178)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Histopathologically Confirmed CIN1+ Associated With Oncogenic HPV Types Detected Within the Lesional Component of the Cervical Tissue Specimen","description":"CIN1+ was defined as CIN grades 1,2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer.\n\nOncogenic HPV types assessed included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at Month 6 in the primary study.","populationDescription":"The analyses was performed on the Total Cohort, which included all enrolled subjects who came at the first visit and received at least one vaccine dose (Cervarix or Placebo)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"Up to year 7","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"191"},{"groupId":"OG001","value":"179"}]}],"classes":[{"title":"Including HPV-16 or 18 (N=191;179)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Without HPV-16 or 18 (N=191;179)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Histopathologically Confirmed CIN1+ Associated With Individual Oncogenic Non-Vaccine HPV Types Detected Within the Lesional Component of the Cervical Tissue Specimen","description":"CIN1+ was defined as CIN grades 1,2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer.\n\nOncogenic HPV types assessed included HPV-31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies and were DNA negative for the corresponding HPV type at Month 6 in the primary study.","populationDescription":"The analyses was performed on the Total Cohort, which included all enrolled subjects who came at the first visit and received at least one vaccine dose (Cervarix or Placebo)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"Up to year 7","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"214"},{"groupId":"OG001","value":"201"}]}],"classes":[{"title":"HPV-31 (N=213;199)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-33 (N=212;199)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-35 (N=211;198)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-39 (N=214;201)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-45 (N=213;200)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-51 (N=207;198)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-52 (N=210;196)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-56 (N=211;201)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-58 (N=213;198)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-59 (N=212;200)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-66 (N=211;195)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-68 (N=213;201)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Histopathologically-confirmed CIN2+ Associated With HPV-16 or HPV-18 Detected Within the Lesional Component of the Cervical Tissue Specimen","description":"CIN2+ was defined as CIN grades 2 and 3, AIS and invasive cervical cancer.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at Month 6 in the primary study.","populationDescription":"The analyses was performed on the Total Cohort, which included all enrolled subjects who came at the first visit and received at least one vaccine dose (Cervarix or Placebo)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"Up to year 7","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"191"},{"groupId":"OG001","value":"178"}]}],"classes":[{"title":"HVP-16/18 (N=191;176)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-16 (N=191;177)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-18 (N=191;178)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Histopathologically Confirmed CIN2+ Associated With Oncogenic HPV Types Detected Within the Lesional Component of the Cervical Tissue Specimen","description":"CIN2+ was defined as CIN grades 2 and 3, AIS and invasive cervical cancer.\n\nOncogenic HPV types assessed included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at Month 6 in the primary study.","populationDescription":"The analyses was performed on the Total Cohort, which included all enrolled subjects who came at the first visit and received at least one vaccine dose (Cervarix or Placebo)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"Up to year 7","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"191"},{"groupId":"OG001","value":"179"}]}],"classes":[{"title":"Including HPV-16 or 18 (N=191;179)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Without HPV-16 or 18 (N=191;179)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Histopathologically Confirmed CIN2+ Associated With Individual Oncogenic Non-Vaccine HPV Types Detected Within the Lesional Component of the Cervical Tissue Specimen","description":"CIN2+ was defined as CIN grades 2 and 3, AIS and invasive cervical cancer.\n\nOncogenic HPV types assessed included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies and were DNA negative for the corresponding HPV type at Month 6 in the primary study.","populationDescription":"The analyses was performed on the Total Cohort, which included all enrolled subjects who came at the first visit and received at least one vaccine dose (Cervarix or Placebo)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"Up to year 7","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"214"},{"groupId":"OG001","value":"201"}]}],"classes":[{"title":"HPV-31 (N=213;200)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-33 (N=212;200)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-35 (N=212;198)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-39 (N=214;201)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-45 (N=213;200)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-51 (N=209;199)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-52 (N=210;198)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-56 (N=211;201)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-58 (N=213;199)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-59 (N=212;200)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-66 (N=212;197)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-68 (N=213;201)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Abnormal Cytology Greater Than or Equal to Atypical Squamous Cells of Undetermined Significance (ASC-US) Associated With an HPV 16 and/or HPV-18 Cervical Infection","description":"Abnormal cytology included atypical squamus cells of undetermined significance (ASC-US), low-grade squamous intraepithelial lesion (LSIL), high-grade squamous intraepithelial lesion (HSIL), atypical glandular cells (AGC), atypical squamus cells and cannot exclude HSIL (ASC-H).\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at Month 6 in the primary study.","populationDescription":"The analyses was performed on the Total Cohort, which included all enrolled subjects who came at the first visit and received at least one vaccine dose (Cervarix or Placebo)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"Up to year 7","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"191"},{"groupId":"OG001","value":"169"}]}],"classes":[{"title":"HPV-16/18 (N=190;158)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-16 (N=190;164)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-18 (N=191;169)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Abnormal Cytology Greater Than or Equal to Atypical Squamous Cells of Undetermined Significance (ASC-US) Associated With Oncogenic HPV Types Cervical Infection","description":"Abnormal cytology included ASC-US, LSIL, HSIL, AGC, and ASC-H.\n\nOncogenic HPV types assessed included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at Month 6 in the primary study.","populationDescription":"The analyses was performed on the Total Cohort, which included all enrolled subjects who came at the first visit and received at least one vaccine dose (Cervarix or Placebo)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"Up to year 7","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"188"},{"groupId":"OG001","value":"176"}]}],"classes":[{"title":"Including HPV-16 or 18 (N=188;175)","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"8"}]}]},{"title":"Without HPV-16 or 18 (N=188;176)","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"8"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Abnormal Cytology Greater Than or Equal to Atypical Squamous Cells of Undetermined Significance (ASC-US) Associated With Individual Oncogenic Non-vaccine HPV Types Cervical Infection","description":"Abnormal cytology included ASC-US, LSIL, HSIL, AGC and ASC-H.\n\nOncogenic HPV types assessed included HPV-31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies and were DNA negative for the corresponding HPV type at month 6 in the primary study.","populationDescription":"The analyses was performed on the Total Cohort, which included all enrolled subjects who came at the first visit and received at least one vaccine dose (Cervarix or Placebo)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"Up to year 7","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"212"},{"groupId":"OG001","value":"198"}]}],"classes":[{"title":"HPV-31 (N=209;192)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-33 (N=210;194)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-35 (N=209;194)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-39 (N=209;189)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-45 (N=212;196)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-51 (N=194;187)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-52 (N=197;176)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}]}]},{"title":"HPV-56 (N=200;194)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-58 (N=206;191)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-59 (N=209;198)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-66 (N=206;186)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-68 (N=210;194)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Abnormal Cytology Greater Than or Equal to Low-grade Squamous Intraepithelial Lesion (LSIL) Associated With an HPV 16 and/or HPV-18 Cervical Infection","description":"Abnormal cytology included ASC-US, LSIL, HSIL, AGC and ASC-H.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at Month 6 in the primary study.","populationDescription":"The analyses was performed on the Total Cohort, which included all enrolled subjects who came at the first visit and received at least one vaccine dose (Cervarix or Placebo)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"Up to year 7","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"191"},{"groupId":"OG001","value":"175"}]}],"classes":[{"title":"HPV-16/18 (N=190;167)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-16 (N=190;170)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-18 (N=191;175)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Abnormal Cytology Greater Than or Equal to Low-grade Squamous Intraepithelial Lesion (LSIL) Associated With Oncogenic HPV Types Cervical Infection","description":"Abnormal cytology included ASC-US, LSIL, HSIL, AGC, and ASC-H.\n\nOncogenic HPV types assessed included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies. Subjects were DNA negative for the 14 oncogenic HPV types and had normal cytology at baseline in the primary study. Subjects with an event were DNA negative for the corresponding HPV type at Month 6 in the primary study.","populationDescription":"The analyses was performed on the Total Cohort, which included all enrolled subjects who came at the first visit and received at least one vaccine dose (Cervarix or Placebo)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"Up to year 7","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"189"},{"groupId":"OG001","value":"178"}]}],"classes":[{"title":"Including HPV-16 or 18 (N=189;178)","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"6"}]}]},{"title":"Without HPV-16 or 18 (N=189;178)","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"6"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Abnormal Cytology Greater Than or Equal to Low-grade Squamous Intraepithelial Lesion (LSIL) Associated With Individual Oncogenic Non-vaccine HPV Types Cervical Infection","description":"Abnormal cytology included ASC-US, LSIL, HSIL, AGC and ASC-H.\n\nOncogenic HPV types assessed included HPV-31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.\n\nSubjects with an event did not report the same event in the earlier studies and were DNA negative for the corresponding HPV type at month 6 in the primary study.","populationDescription":"The analyses was performed on the Total Cohort, which included all enrolled subjects who came at the first visit and received at least one vaccine dose (Cervarix or Placebo)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"Up to year 7","groups":[{"id":"OG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."},{"id":"OG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"212"},{"groupId":"OG001","value":"199"}]}],"classes":[{"title":"HPV-31 (N=210;194)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-33 (N=211;197)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-35 (N=209;196)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-39 (N=211;192)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-45 (N=212;197)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-51 (N=203;190)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-52 (N=202;184)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]},{"title":"HPV-56 (204;194)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-58 (N=209;195)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"HPV-59 (N=212;199)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-66 (N=209;187)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"HPV-68 (N=211;198)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Serious adverse events: during the follow-up period up to Year 9.","description":"Only serious adverse events were assessed in the study and no other symptoms.","eventGroups":[{"id":"EG000","title":"Cervarix Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study.","seriousNumAffected":20,"seriousNumAtRisk":224,"otherNumAffected":0,"otherNumAtRisk":0},{"id":"EG001","title":"Placebo Group","description":"Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study.","seriousNumAffected":11,"seriousNumAtRisk":213,"otherNumAffected":0,"otherNumAtRisk":0}],"seriousEvents":[{"term":"Abortion spontaneous incomplete","organSystem":"Pregnancy, puerperium and perinatal conditions","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":224},{"groupId":"EG001","numAffected":1,"numAtRisk":213}]},{"term":"Abortion missed","organSystem":"Pregnancy, puerperium and perinatal conditions","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":224},{"groupId":"EG001","numAffected":2,"numAtRisk":213}]},{"term":"Appendicitis","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":224},{"groupId":"EG001","numAffected":0,"numAtRisk":213}]},{"term":"Bipolar disorder","organSystem":"Psychiatric disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":224},{"groupId":"EG001","numAffected":1,"numAtRisk":213}]},{"term":"Abortion spontaneous","organSystem":"Pregnancy, puerperium and perinatal conditions","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":224},{"groupId":"EG001","numAffected":0,"numAtRisk":213}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":224},{"groupId":"EG001","numAffected":0,"numAtRisk":213}]},{"term":"Bacterial pyelonephritis","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":224},{"groupId":"EG001","numAffected":0,"numAtRisk":213}]},{"term":"Benign hydatidiform mole","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":224},{"groupId":"EG001","numAffected":1,"numAtRisk":213}]},{"term":"Blighted ovum","organSystem":"Pregnancy, puerperium and perinatal conditions","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":224},{"groupId":"EG001","numAffected":1,"numAtRisk":213}]},{"term":"Bronchiectasis","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":224},{"groupId":"EG001","numAffected":0,"numAtRisk":213}]},{"term":"Depression suicidal","organSystem":"Psychiatric disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":224},{"groupId":"EG001","numAffected":0,"numAtRisk":213}]},{"term":"Ectopic pregnancy","organSystem":"Pregnancy, puerperium and perinatal conditions","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":224},{"groupId":"EG001","numAffected":0,"numAtRisk":213}]},{"term":"Erysipelas","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":224},{"groupId":"EG001","numAffected":1,"numAtRisk":213}]},{"term":"Gestational diabetes","organSystem":"Metabolism and nutrition disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":224},{"groupId":"EG001","numAffected":0,"numAtRisk":213}]},{"term":"Intra-uterine death","organSystem":"Pregnancy, puerperium and perinatal conditions","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":224},{"groupId":"EG001","numAffected":1,"numAtRisk":213}]},{"term":"Intracranial pressure increased","organSystem":"Nervous system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":224},{"groupId":"EG001","numAffected":0,"numAtRisk":213}]},{"term":"Myelitis","organSystem":"Nervous system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":224},{"groupId":"EG001","numAffected":0,"numAtRisk":213}]},{"term":"Nephrolithiasis","organSystem":"Renal and urinary disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":224},{"groupId":"EG001","numAffected":0,"numAtRisk":213}]},{"term":"Oligohydramnios","organSystem":"Pregnancy, puerperium and perinatal conditions","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":224},{"groupId":"EG001","numAffected":1,"numAtRisk":213}]},{"term":"Ovarian cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":224},{"groupId":"EG001","numAffected":1,"numAtRisk":213}]},{"term":"Peptic ulcer","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":224},{"groupId":"EG001","numAffected":1,"numAtRisk":213}]},{"term":"Pneumonia primary atypical","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":224},{"groupId":"EG001","numAffected":0,"numAtRisk":213}]},{"term":"Pre-eclampsia","organSystem":"Pregnancy, puerperium and perinatal conditions","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":224},{"groupId":"EG001","numAffected":1,"numAtRisk":213}]},{"term":"Pyelonephritis","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":224},{"groupId":"EG001","numAffected":1,"numAtRisk":213}]},{"term":"Renal artery thrombosis","organSystem":"Renal and urinary disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":224},{"groupId":"EG001","numAffected":0,"numAtRisk":213}]},{"term":"Suicide attempt","organSystem":"Psychiatric disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":224},{"groupId":"EG001","numAffected":0,"numAtRisk":213}]},{"term":"Varicose vein","organSystem":"Vascular disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":224},{"groupId":"EG001","numAffected":0,"numAtRisk":213}]}]},"moreInfoModule":{"limitationsAndCaveats":{"description":"Interim analysis at Year 7 and Year 8 are superseded by the final analysis at Year 9."},"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."},"pointOfContact":{"title":"GSK Response Center","organization":"GlaxoSmithKline","phone":"866-435-7343"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D030361","term":"Papillomavirus Infections"}],"ancestors":[{"id":"D015229","term":"Sexually Transmitted Diseases, Viral"},{"id":"D012749","term":"Sexually Transmitted Diseases"},{"id":"D003141","term":"Communicable Diseases"},{"id":"D007239","term":"Infections"},{"id":"D004266","term":"DNA Virus Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D014412","term":"Tumor Virus Infections"},{"id":"D000091662","term":"Genital Diseases"},{"id":"D000091642","term":"Urogenital Diseases"},{"id":"D020969","term":"Disease Attributes"},{"id":"D010335","term":"Pathologic Processes"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"}]},"interventionBrowseModule":{"meshes":[{"id":"D001800","term":"Blood Specimen Collection"},{"id":"C510352","term":"human papillomavirus vaccine, L1 type 16, 18"}],"ancestors":[{"id":"D013048","term":"Specimen Handling"},{"id":"D019411","term":"Clinical Laboratory Techniques"},{"id":"D019937","term":"Diagnostic Techniques and Procedures"},{"id":"D003933","term":"Diagnosis"},{"id":"D011677","term":"Punctures"},{"id":"D013514","term":"Surgical Procedures, Operative"},{"id":"D008919","term":"Investigative Techniques"}]}},"hasResults":true}